Antibody
By developing antibodies with high affinity and selective blocking of CSF-1R, the shortcomings of existing anti-CSF-1R antibodies in the treatment of cancer and fibrosis have been overcome, achieving effective treatment for cancer and fibrosis.
Patent Information
- Application Number
- CN202011009068.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2013-08-30
- Filing Date
- 2014-08-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2034-08-26
AI Technical Summary
There is a lack of effective anti-CSF-1R antibodies in the current technology for the treatment of cancer and fibrotic diseases, especially fibrotic diseases, where the treatment effect is limited and there is a lack of targeted therapies and antibody therapies.
An anti-CSF-1R antibody or its binding fragment containing a specific CDR sequence in the heavy and light chains has been developed. This antibody can block the binding of CSF-1R to its ligand with high affinity, block signal transduction, and selectively deplete atypical monocyte populations to prevent internalization, for the treatment of cancer and fibrotic diseases.
This antibody can effectively block CSF-1R signaling, reduce the infiltration of tumor-associated macrophages, and inhibit the fibrotic process, providing therapeutic potential for cancer and fibrotic diseases.
Smart Images

Figure CN112321711B_ABST
Abstract
Description
[0001] This application is a divisional application of CN201480057403.8. Technical Field
[0002] The present invention relates to anti-CSF-1R antibodies and binding fragments thereof, DNA encoding anti-CSF-1R antibodies and binding fragments thereof, host cells comprising said DNA, and methods for expressing said antibodies or binding fragments in host cells. The present invention also extends to pharmaceutical compositions comprising said antibodies or binding fragments thereof, and the use of said antibodies, binding fragments, and compositions comprising said antibodies and binding fragments in treatment. Background Art
[0003] Colony stimulating factor 1 (CSF-1), also known as macrophage colony stimulating factor (M-CSF), is a cytokine produced by various cells, including macrophages, endothelial cells and fibroblasts. CSF-1 contains two "monomer" polypeptides that form the biologically active dimer CSF-1 protein. Due to RNA alternative splicing, CSF-1 exists in at least three mature forms (see Cerretti et al., 1988, Molecular Immunology, 25: 761). These three forms of CSF-1 are translated from different rnRNA precursors, which encode polypeptide monomers of 256 to 554 amino acids, with a signal sequence of 32 amino acids at the amino terminus and a putative transmembrane region of approximately 23 amino acids near the carboxyl terminus. Subsequently, the precursor peptide is processed by amino-terminal and carboxyl-terminal proteolytic cleavage to release mature CSF-1. Residues 1-149 of all three mature forms of CSF-1 are identical and are believed to contain sequences essential for the biological activity of CSF-1. In vivo, CSF-1 monomers are glycosylated and dimerize via disulfide bonds. CSF-1 belongs to a group of biological agonists that promote the production of blood cells. Specifically, it acts as a growth and differentiation factor for myeloid progenitor cells of the mononuclear phagocyte lineage. In addition, CSF-1 stimulates the survival, proliferation, and function of macrophages through specific receptors on responding cells.
[0004] CSF-1 receptor (CSF-1R) is also known as c-fms gene product or CD115. CSF-1R is a 165kDa type 1 TM glycoprotein, which belongs to the type III receptor tyrosine kinase family. It has also been shown that, in addition to CSF-1, the structurally similar but sequence-independent molecule IL-34 is also a ligand for CSF-1R (Lin et al., 2008, Science 320: 807-811). The expression of CSF-1R is confined to cells of the monocyte-macrophage lineage (circulation and resident tissue colonies) and osteoclasts. In addition, it is expressed in many cells of the female reproductive system, including oocytes, decidual cells and trophoblasts.
[0005] Binding of the ligand CSF-1 to the CSF-1 receptor results in phosphorylation of the receptor on one or more tyrosine residues through the action of the tyrosine kinase domain. This phosphorylation can be detected because antibodies are available that only bind to the receptor after phosphorylation (e.g. Phospho-M-CSF-Receptor (Tyr546) antibody #3083 from Cell Signaling Technology).
[0006] Expression of CSF-1 and CSF-1R is associated with tumor progression and poor diagnosis in many cancer types. Tumor-associated macrophages (TAMs) can be a major component of the tumor stroma and high levels of CSF-1 and CSF-1R are associated with high TAM infiltration and poor prognosis in many tumor types.
[0007] Antibodies against CSF-1R are known in the art. Sherr, CJ et al., 1989, Blood 73: 1786-1793 describes anti-CSF-1R antibodies that inhibit CSF-1 activity (Sherr, CJ et al., 1989, Blood 73: 1786-1793). WO2009 / 026303 discloses anti-CSF-1R antibodies that bind to human CSF-1R and an in vivo mouse tumor model using anti-mouse CSF-1R antibodies. WO2011 / 123381 discloses anti-CSF-1R antibodies that internalize CSF-1R and have ADCC activity. WO2011 / 123381 also discloses an in vivo mouse tumor model using anti-mouse CSF-1R antibodies. WO2011 / 140249 discloses anti-CSF-1R antibodies that block the binding of CSF-1 to CSF-1R, which are considered to be useful in treating cancer. WO2009 / 112245 discloses an anti-CSF-1R IgG1 antibody that inhibits CSF-1 from binding to CSF-1R, which is considered to be useful in treating cancer, inflammatory bowel disease and rheumatoid arthritis. WO2011 / 131407 discloses an anti-CSF-1R antibody that inhibits CSF-1 from binding to CSF-1R, which is considered to be useful in treating bone loss and cancer. WO2011 / 107553 discloses an anti-CSF-1R antibody that inhibits CSF-1 from binding to CSF-1R, which is considered to be useful in treating bone loss and cancer. WO2011 / 070024 discloses an anti-CSF-1R antibody that binds to the human CSF-1R fragment delD4.
[0008] There is a need in the art to provide novel anti-CSF-1R antibodies suitable for therapeutic applications.While therapeutic applications of anti-CSF-1R antibodies in the treatment of certain cancers have been previously described, there remains a need to provide novel therapeutic applications of such antibodies.
[0009] The term "fibrotic disease" refers to an abnormal wound healing response in which excess fibrous connective tissue forms in an organ or tissue. The deposition and accumulation of excess extracellular matrix components (such as collagen and fibronectin) leads to hardening and scarring of tissues, which can ultimately lead to organ failure.
[0010] Examples of fibrotic diseases include pulmonary fibrosis such as idiopathic pulmonary fibrosis and cystic fibrosis, renal fibrosis, liver fibrosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloids, myocardial infarction, systemic sclerosis, scleroderma, and arthrofibrosis.
[0011] Trauma leads to immediate coagulation and coagulation reaction along with the development of temporary extracellular matrix (ECM). Platelet aggregation and activation help promote the inflammatory reaction characterized by vasodilation and increased vascular permeability, thereby recruiting various immune cells (including neutrophils, macrophages, eosinophils and lymphocytes). Neutrophils and macrophages carry out debridement to wounds, thereby reducing the risk of infection, and secrete various growth factors and cytokines for further amplifying inflammatory reactions together with activated lymphocytes. Molecular activation macrophages such as TGFβ, PDGF, IL-13 also lead to the recruitment, proliferation and activation of fibroblasts at wound sites. Activated fibroblasts or myofibroblasts are characterized by expressing α-smooth muscle actin and secreting collagen and other ECM components. Activated fibroblasts contract collagen lattice (collagenlattice), thereby the edge of the wound is pulled to the center. Epidermis and endothelial cells proliferate and migrate on temporary matrix to regenerate damaged tissue, thereby completing wound repair.
[0012] Sustained tissue injury or damage, or dysregulation of repair pathways results in an inappropriate wound response. Excessive deposition and hypercrosslinking of collagen and ECM occur, leading to excessive formation and hardening of scar tissue that replaces normal tissue architecture.
[0013] The cause of fibrotic diseases may depend on the organs or tissues involved and is unknown in some diseases such as idiopathic pulmonary fibrosis (IPF). Liver fibrosis and eventual cirrhosis result from persistent chronic liver damage by exposure to various factors including environmental and dietary factors or infectious agents. Long-term hepatitis B or hepatitis C infection can lead to liver fibrosis. Continuous excessive consumption of alcohol or a high fat / sugar diet can also lead to sclerosis of the liver. Similarly, diabetes may damage the kidneys and leave scars, leading to loss of function.
[0014] IPF is one of seven interstitial lung diseases with unknown causes. Environmental factors such as radiation exposure or particles may play a role. Subjects who smoke are also at higher risk for the disease. After diagnosis, patients have a very short lifespan, with an average survival rate of 2-5 years.
[0015] The treatment of fibrotic diseases usually includes anti-inflammatory and immunosuppressive drugs, but these are less beneficial to patients. The lack of efficacy of these treatments makes IPF and fibrotic diseases generally reconsidered as abnormal responses to wound healing rather than inflammatory conditions. Pirfenidone is a small molecule drug approved for the treatment of IPF in Japan in 2008 and in Europe in 2011, which may work through multiple mechanisms of action. So far, no targeted therapy and antibody therapy have been approved for fibrotic indications.
[0016] Therefore, there is currently an unmet medical need for improved treatments for fibrotic diseases.For example, for IPF, the 3-year survival rate is 50% while the 5-year survival rate is only 20%, and transplantation is required in approximately 20% of cases. SUMMARY OF THE INVENTION
[0017] In one aspect, an anti-CSF-1R antibody or binding fragment thereof comprising a heavy chain is provided, wherein the variable domain of the heavy chain comprises at least one of a CDR having a sequence as shown in SEQ ID NO: 4 for CDR-H1, a CDR having a sequence as shown in SEQ ID NO: 5 for CDR-H2, and a CDR having a sequence as shown in SEQ ID NO: 6 for CDR-H3, for example, wherein CDR-H1 is SEQ ID NO: 4, CDR-H2 is SEQ ID NO: 5, and CDR-H3 is SEQ ID NO: 6.
[0018] In one aspect, an antibody or binding fragment according to the present disclosure comprises a light chain, wherein the variable domain of the light chain comprises at least one of a CDR having a sequence as shown in SEQ ID NO: 1 for CDR-L1, a CDR having a sequence as shown in SEQ ID NO: 2 for CDR-L2, and a CDR having a sequence as shown in SEQ ID NO: 3 for CDR-L3, e.g., wherein CDR-L1 is SEQ ID NO: 1, CDR-L2 is SEQ ID NO: 2, and CDR-L3 is SEQ ID NO: 3.
[0019] The antibodies of the present disclosure have high affinity for CSF-1R, are able to block the binding of ligands to CSF-1R, do not activate CSF-1R, and do not cause internalization of CSF-1R.
[0020] The present disclosure also extends to polynucleotides (such as DNA) encoding the antibodies or fragments as described herein.
[0021] A host cell comprising the polynucleotide is also provided.
[0022] Also provided herein are methods of expressing the antibodies or binding fragments thereof.
[0023] The present disclosure also relates to pharmaceutical compositions comprising the antibodies or binding fragments thereof.
[0024] In one embodiment, a method of treatment is provided, comprising administering a therapeutically effective amount of an antibody, fragment or composition as described herein.
[0025] The present disclosure also extends to the use of the antibodies, binding fragments or compositions of the present disclosure for therapy, in particular for the treatment of cancer and / or fibrotic diseases. DETAILED DESCRIPTION OF THE INVENTION
[0026] In one embodiment, the antibodies provided by the present invention are capable of blocking ligand binding to CSF-1R. As used herein, blocking refers to physical blocking, such as blocking the receptor, but also includes situations where the antibody or fragment binds to an epitope, which causes, for example, a conformational change, meaning that the natural ligand of the receptor no longer binds (referred to herein as allosteric blocking or allosteric inhibition). In one embodiment, the antibodies of the present disclosure bind to all isoforms of CSF-1R, for example, those with alterations in the ECD domain (such as V23G, A245S, H247P, V279M and combinations of two, three or four of said alterations).
[0027] An assay suitable for determining the ability of an antibody to block CSF-1R is described in the Examples herein. Both CSF-1 and IL-34 are ligands for CSF-1R and the antibodies of the invention preferably inhibit the activity of both CSF-1 and IL-34 in a functional cell screen. The antibodies of the invention also preferably do not cause CSF-1R activation and / or CSF-1R internalization. The antibodies of the invention also preferably selectively deplete atypical populations of monocytes in vivo.
[0028] Atypical monocytes generally refer to monocytes with low expression of CD14 and high expression of CD 16. This monocyte population is considered to be the precursor of tumor-associated macrophages.
[0029] The antibody molecules of the invention suitably have a high binding affinity. As described in the Examples herein, affinity may be measured using any suitable method known in the art, including techniques such as surface plasmon resonance (e.g. BIAcore), using isolated native or recombinant CSF-1R or a suitable fusion protein / polypeptide. In one example, as described in the Examples herein, affinity is measured using a recombinant human CSF-1R extracellular domain. In one example, the recombinant human CSF-1R extracellular domain used is a monomer. Suitably, the antibody molecules of the invention have a binding affinity of about 1 nM or less for isolated human CSF-1R. In one embodiment, the antibody molecules of the invention have a binding affinity of about 500 pM or less. In one embodiment, the antibody molecules of the invention have a binding affinity of about 250 pM or less. In one embodiment, the antibody molecules of the invention have a binding affinity of about 200 pM or less. In one embodiment, the invention provides an anti-CSF-1R antibody having a binding affinity of about 100 pM or less. In one embodiment, the present invention provides a humanized anti-CSF-1R antibody having a binding affinity of about 100 pM or less (preferably about 10 pM or less, more preferably about 5 pM or less). In another embodiment, the present invention provides a humanized anti-CSF-1R antibody having a binding affinity of about 100 pM or less (preferably about 10 pM or less, more preferably about 5 pM or less).
[0030] The smaller the affinity numerical value, the greater the affinity of the antibody or fragment for the antigen.
[0031] As used herein, human CSF-1R refers to the human protein named CSF-1R or a biologically active fragment thereof, for example, as shown in SEQ ID NO: 39 or registered in UniProt under the number P07333. Of course, the expressed mature protein does not include the signal sequence, as the signal sequence is cleaved after translation.
[0032] The present inventors have provided novel anti-CSF-1R antibodies, including humanized antibodies. Antibodies were generated from immunization of rats with rat fibroblasts transfected with a vector expressing the extracellular domain of CSF-1R. Primary screening of supernatants for human CSF-1R binding of the antibodies identified approximately 1000 wells containing antibodies with anti-CSF-1R activity. Secondary screening for antibodies capable of preventing binding of human CSF-1 to human CSF-1R identified 88 positive wells. Tertiary screening for antibodies capable of preventing CSF-1-dependent survival of primary human monocytes identified 18 positive wells. The variable regions of these 18 positive wells were cloned, which resulted in the successful cloning of 14 antibodies, and subsequent expression provided 9 chimeric anti-CSF-1R antibodies that were expressed at sufficient levels and capable of inhibiting CSF-1 binding. These 9 antibodies were sequenced and found to all have unique sequences and were used for further studies.
[0033] These nine anti-CSF-1R chimeric antibodies were evaluated for their ligand blocking activity and ability to inhibit CSF-1 and IL-34 mediated monocyte survival. Four of the antibodies were prioritized for further studies because they demonstrated complete inhibition of CSF-1 binding and high levels of monocyte survival inhibition. The activity of these four anti-CSF-1R chimeric antibodies was tested in a number of in vitro assays to assess affinity, inhibition of CSF-1 binding, cross-reactivity with rhesus monkey, cynomolgus monkey and canine CSF-1R, CSF-1R internalization and CSF-1R activation. These four anti-CSF-1R antibodies were also humanized and the affinity of the humanized grafts was measured. Humanization of two of the anti-CSF-1R antibodies produced chimeric antibodies with an affinity (K) equivalent to that of the parent chimeric antibody. D ) and a fully humanized antibody (absence of rat donor residues) indicating that the antibody has a Tm of appropriate thermal stability. In contrast, the other two humanized anti-CSF-1R antibodies had reduced affinity for CSF-1R relative to the chimeric antibody and a smaller Tm. For these reasons, only the fully humanized grafts of two of the antibodies that retained affinity were expressed on a larger scale for further analysis.
[0034] Further analysis of fully humanized grafts of these two antibodies was performed and an MCP-1 inhibition assay was performed, wherein inhibition of CSF-1R signaling by an antibody that blocks CSF-1 binding results in reduced MCP-1 secretion levels. This assay surprisingly shows that fully humanized grafts exhibit reduced activity compared to chimeric antibodies. A series of experiments were performed to reveal the reasons why fully humanized grafts exhibit this reduced activity to a preferred antibody (referred to as Ab969). Many intermediate humanized grafts of Ab969 were produced and tested in an MCP-1 inhibition assay. It was found that grafts comprising variable light chain donor residue Y71 generally showed activity comparable to chimeric Ab969 in an MCP-1 inhibition assay. It has been hypothesized that the differences in activity of various antibody grafts in the MCP-1 inhibition assay are due to changes in antibody association rate compared to chimeric Ab969 (reduced K a ).
[0035] Comparison of thermal stability analysis of Ab969 with other anti-CSF-1R antibodies (eg, anti-CSF-1R antibody Ab970) showed that Ab969 may be more stable.
[0036] Further biophysical analysis of humanized grafts of Ab969 showed that some grafts precipitated upon concentration of the antibody. It has been shown that substitution of the lysine residue at position 38 in the light chain (eg glutamine) results in improved physical stability.
[0037] Therefore, an antibody graft of Ab969, Ab969.g2 (also referred to as Ab969), was selected for further in vitro characterization studies. In addition to the favorable high CSF-1R binding affinity, high thermal stability, and high physical stability, the antibody also exhibited good inhibition of IL-34-dependent monocyte activation and was also found to be able to bind to the SNP variant of CSF-1R. Ab969.g2 was also used for pharmacodynamic marker analysis in cynomolgus monkeys, where it was shown that Ab969.g2 bound to CSF-1R, blocked CSF-1 binding, and selectively depleted an atypical population of cynomolgus monkey monocytes in vivo, which are precursor cells of tumor-associated macrophages.
[0038] Thus, in one embodiment, the present invention provides an antibody comprising a heavy chain and / or a light chain, wherein the heavy chain and / or the light chain comprises at least one CDR derived from the anti-CSF-1R antibody 969.2.
[0039] Ab969.2 is a full-length humanized IgG4 molecule; the light chain contains a human kappa chain constant region (Km3 allotype) and the heavy chain contains a human gamma-4 heavy chain constant region with a hinge stabilizing mutation S241P (Angal et al., 1993). A potential DG isomerization motif is present at the junction of CDR-L2 and the framework in the light chain variable region. The sequences of the Ab969.2 full antibody heavy and light chains are shown in SEQ ID NOs: 27 and 19.
[0040] The residues in the variable domains of antibodies are conventionally numbered according to the system devised by Kabat et al., 1987. The system is shown in Kabat et al., 1987, Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (hereinafter referred to as "Kabat et al. (supra)"). Unless otherwise indicated, this numbering system is used in this specification.
[0041] The Kabat residue nomenclature does not always correspond directly to the linear numbering of amino acid residues. The actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering, which corresponds to shortening or insertion of structural components of the basic variable domain structure, whether framework or complementarity determining region (CDR). The correct residue Kabat numbering for a given antibody can be determined by alignment of homologous residues in the antibody sequence with the "standard" Kabat numbering sequence.
[0042] According to the Kabat numbering system, the CDRs of the heavy chain variable domain are located at residues 31-35 (CDR-H1), residues 50-65 (CDR-H2), and residues 95-102 (CDR-H3). However, according to Chothia (Chothia, C. and Lesk, AM, J. Mol. Biol., 196, 901-917 (1987)), the loop equivalent to CDR-H1 extends from residue 26 to residue 32. Therefore, unless otherwise indicated, "CDR-H1" as used herein means residues 26 to 35, as described by combining the Kabat numbering system and the Chothia topological loop definition.
[0043] According to the Kabat numbering system, the CDRs of the light chain variable domain are located at residues 24-34 (CDR-L1), residues 50-56 (CDR-L2), and residues 89-97 (CDR-L3).
[0044] Antibodies used in the present disclosure can be obtained using any suitable method known in the art. CSF-1R polypeptides / proteins (including fusion proteins), cells expressing the polypeptides (recombinantly or naturally) can be used to produce antibodies that specifically recognize CSF-1R. The polypeptides can be "mature" polypeptides or biologically active fragments or derivatives thereof. The human protein is registered in UniProt under the number P07333.
[0045] The polypeptides used to immunize the host can be prepared from genetically modified host cells including expression systems by methods well known in the art, or they can be recovered from natural biological sources. In this application, the term "polypeptide" includes peptides, polypeptides and proteins. Unless otherwise indicated, these words are used interchangeably. In some cases, the CSF-1R polypeptide can be part of a larger protein (such as a fusion protein, for example fused to an affinity tag, etc.).
[0046] Where immunization of animals is necessary, antibodies raised against CSF-1R polypeptides can be obtained by administering the polypeptides to animals (preferably non-human animals) using well-known and conventional protocols, see, for example, Handbook of Experimental Immunology, DM Weir (ed.), Vol 4, Blackwell Scientific Publishers, Oxford, England, 1986. Many warm-blooded animals (such as rabbits, mice, rats, sheep, cattle, camels or pigs) can be immunized. However, mice, rabbits, pigs and rats are generally the most suitable.
[0047] Monoclonal antibodies can be prepared by any method known in the art, such as the hybridoma technology (Kohler & Milstein, 1975, Nature, 256: 495-497), the trioma technology, the human B-cell hybridoma technology (Kozbor et al., 1983, Immunology Today, 4: 72) and the EBV-hybridoma technology (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, pp77-96, Alan R Liss, Inc.).
[0048] Antibodies can also be produced using the single lymphocyte antibody method, such as that described by Babcook, J. et al., 1996, Proc. Natl. Acad. Sci. USA 93:7843-7848, WO92 / 02551, WO04 / 051268, and International Patent Application No. WO2004 / 106377, by cloning and expressing immunoglobulin variable region cDNAs produced from a single lymphocyte selected for specific antibody production.
[0049] Screening of antibodies can be performed using assays that measure binding to human CSF-1R and / or assays that measure the ability to block ligand binding to the receptor. Examples of suitable assays are described in the Examples herein.
[0050] As used herein, "specificity" refers to an antibody that recognizes only the antigen to which it is specifically directed or has a significantly higher binding affinity for the antigen to which it is specifically directed than for the antigen to which it is non-specifically directed, for example, at least 5, 6, 7, 8, 9, or 10 times higher binding affinity.
[0051] The amino acid sequences and polynucleotide sequences of certain antibodies of the present disclosure are provided in Figures 1 and 2.
[0052] In one aspect of the present invention, the antibody is an anti-CSF-1R antibody or a binding fragment thereof comprising a heavy chain, wherein the variable domain of the heavy chain comprises at least one of a CDR having the sequence shown in SEQ ID NO: 4 for CDR-H1, a CDR having the sequence shown in SEQ ID NO: 5 for CDR-H2, and a CDR having the sequence shown in SEQ ID NO: 6 for CDR-H3. Preferably, the variable domain of the heavy chain comprises the sequence shown in SEQ ID NO: 4 for CDR-H1, the sequence shown in SEQ ID NO: 5 for CDR-H2, and the sequence shown in SEQ ID NO: 6 for CDR-H3.
[0053] In the second aspect of the present invention, the antibody is an anti-CSF-1R antibody or a binding fragment thereof comprising a light chain, wherein the variable domain of the light chain comprises at least one of a CDR having a sequence as shown in SEQ ID NO: 1 for CDR-L1, a CDR having a sequence as shown in SEQ ID NO: 2 for CDR-L2, and a CDR having a sequence as shown in SEQ ID NO: 3 for CDR-L3. Preferably, the variable domain of the light chain comprises a sequence as shown in SEQ ID NO: 1 for CDR-H1, a sequence as shown in SEQ ID NO: 2 for CDR-H2, and a sequence as shown in SEQ ID NO. 3 for CDR-H3.
[0054] In one embodiment, the antibody of the invention is an anti-CSF-1R antibody or a binding fragment thereof comprising a heavy chain as defined above and further comprising a light chain, wherein the variable domain of the light chain comprises at least one of a CDR having the sequence shown in SEQ ID NO: 1 for CDR-L1, a CDR having the sequence shown in SEQ ID NO: 2 for CDR-L2, and a CDR having the sequence shown in SEQ ID NO: 3 for CDR-L3. The variable domain of the light chain preferably comprises the sequence shown in SEQ ID NO: 1 for CDR-L1, the sequence shown in SEQ ID NO: 2 for CDR-L2, and the sequence shown in SEQ ID NO: 3 for CDR-L3.
[0055] In one embodiment, at least one amino acid in one or more CDRs selected from the group independently consisting of:
[0056] Any one of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3;
[0057] any one of the combinations CDR-H1 and H2, CDR-H1 and H3, CDR-H1 and L1, CDR-H1 and L2, CDR-H1 and L3, CDR-H2 and H3, CDR-H2 and L1, CDR-H2 and L2, CDR-H2 and L3, CDR-H3 and L1, CDR-H3 and L2, CDR-H3 and L3, CDR-L1 and L2, CDR-L1 and L3, CDR-L2 and L3;
[0058] CDR-H1, H2 and H3, CDR-H1, H2 and L1, CDR-H1, H2 and L2, CDR-H1, H2 and L3, CDR-H2, H3 and L1, CDR-H2, H3 and L2, CDR-H2, H3 and L3, CDR-H3, L1 and L2, CDR-H3, L1 and L3, CDR-L1, L2, L3;
[0059] any one of the combinations CDR-H1, H2, H3 and L1, CDR-H1, H2, H3 and L2, CDR-H1, H2, H3 and L3, CDR-H2, H3, L1 and L2, CDR-H2, H3, L2 and L3, CDR-H3, L1, L2 and L3, CDR-L1, L2, L3 and H1, CDR-L1, L2, L3 and H2, CDR-L1, L2, L3 and H3, CDR-L2, L3, H1 and H2;
[0060] CDR-H1, H2, H3, L1 and L2, CDR-H1, H2, H3, L1 and L3, CDR-H1, H2, H3, L2 and L3, CDR-L1, L2, L3, H1 and H2, CDR-L1, L2, L3, H1 and H3, CDR-L1, L2, L3, H2 and H3; and
[0061] Combined CDRs - H1, H2, H3, L1, L2 and L3.
[0062] In one embodiment, the domain of a heavy chain disclosed herein comprises a sequence with 1, 2, 3 or 4 conservative amino acid substitutions, e.g., wherein the substitutions are in framework.
[0063] In one embodiment, the framework of the heavy chain variable region comprises 1, 2, 3, or 4 amino acids that have been inserted, deleted, substituted, or a combination thereof. In one embodiment, the substituted amino acids are the corresponding amino acids from a donor antibody.
[0064] In one embodiment, a light chain variable region disclosed herein comprises a sequence having 1, 2, 3 or 4 conservative amino acid substitutions, e.g., wherein the substitutions are in framework.
[0065] In one embodiment, the framework of the light chain variable region comprises 1, 2, 3 or 4 amino acids that have been inserted, deleted, substituted or a combination thereof. In one embodiment, the substituted amino acids are the corresponding amino acids from a donor antibody.
[0066] In one aspect of the present invention, an anti-CSF-1R antibody or a binding fragment thereof is provided, wherein the variable domain of the heavy chain comprises three CDRs and the sequence of CDR-H1 has at least 60%, 70%, 80%, 90% or 95% identity or similarity to the sequence shown in SEQ ID NO:4, the sequence of CDR-H2 has at least 60%, 70%, 80%, 90% or 95% identity or similarity to the sequence shown in SEQ ID NO:5, and the sequence of CDR-H-3 has at least 60%, 70%, 80%, 90% or 95% identity or similarity to the sequence shown in SEQ ID NO:6. Preferably, the anti-CSF-1R antibody or binding fragment thereof further comprises a light chain, wherein the variable domain of the light chain comprises three CDRs and the sequence of CDR-L1 has at least 60%, 70%, 80%, 90% or 95% identity or similarity to the sequence shown in SEQ ID NO: 1, the sequence of CDR-L2 has at least 60%, 70%, 80%, 90% or 95% identity or similarity to the sequence shown in SEQ ID NO: 2, and the sequence of CDR-L3 has at least 60% identity or similarity to the sequence shown in SEQ ID NO: 3.
[0067] In one embodiment, the variable region is provided having at least 60%, 70%, 80%, 90% or 95% identity or similarity to the variable region sequences disclosed herein. In another embodiment, an anti-CSF-1R antibody is provided that competes with an antibody or fragment of the invention for binding to a CSF-1R receptor, preferably the extracellular domain of the CSF-1R receptor, more specifically to a CSF-1R receptor having a sequence of SEQ ID NO: 35, 36, 37, 38 and / or 39 or UniProt database entry P07333, specifically to the extracellular domain of the CSF-1R receptor having SEQ ID NO: 36 or 498 amino acids of the extracellular domain disclosed in UniProt database entry P07333 (amino acids 20 to 517 of P07333).
[0068] In one embodiment, a cross-blocking anti-CSF-1R antibody is provided, which comprises antibodies for the six CDRs shown in the sequence SEQ ID NO: 1 for CDR-L1, SEQ ID NO: 2 for CDR-L2, SEQ ID NO: 3 for CDR-L3, SEQ ID NO: 4 for CDR-H1, SEQ ID NO: 5 for CDR-H2 and SEQ ID NO: 6 for CDR-H3, for example with an affinity binding of 100 pM or less, in particular, wherein the cross-blocking is allosteric.
[0069] In another embodiment, an anti-CSF-1R-antibody or a binding fragment thereof is provided which inhibits or overlaps with the binding of CSF-1 and / or IL-34 to the extracellular domain of the CSF-1R receptor.
[0070] In one embodiment, an anti-CSF-1R antibody is provided which cross-blocks an antibody comprising six CDRs as shown in SEQ ID NO: 1 for CDR-L1, SEQ ID NO: 2 for CDR-L2, SEQ ID NO: 3 for CDR-L3, SEQ ID NO: 4 for CDR-H1, SEQ ID NO: 5 for CDR-H2 and SEQ ID NO: 6 for CDR-H3, for example with an affinity of 100 pM or less, wherein the antibody cross-blocks binding by binding to the same epitope as the antibody it blocks.
[0071] In one embodiment, an antibody or binding fragment thereof is provided in which the C-terminal residue of the antibody sequence (e.g., the C-terminal residue of the heavy chain sequence, e.g., the terminal lysine) is cleaved. In one embodiment, the amino acid is cleaved from the sequence disclosed herein. Generally, cleavage results from post-translational modification of the expressed antibody or binding fragment.
[0072] In another embodiment, an anti-CSF-1R antibody of any of the above or below embodiments is provided, wherein the C-terminal lysine of the heavy chain sequence shown in SEQ ID NO: 27 or SEQ ID NO: 29 is deleted or deleted. The deleted or deleted C-terminal lysine (e.g., position 453 of SEQ ID NO: 27 or position 472 of SEQ ID NO: 30) can be achieved, for example, by expressing the anti-CSF-1R antibody in an expression system without encoding the terminal lysine. Alternatively, the deletion of the C-terminal residue (such as lysine) can be achieved as a post-translational modification.
[0073] In one embodiment, the antibodies or binding fragments of the invention are humanized.
[0074] The term "humanized antibody" as used herein refers to an antibody or antibody molecule in which the heavy chain and / or light chain contains one or more CDRs (including one or more modified CDRs if necessary) from a donor antibody (e.g., a mouse monoclonal antibody) that is transplanted into the heavy chain and / or light chain variable region framework of a recipient antibody (e.g., a human antibody) (see, e.g., US 5,585,089; WO91 / 09967). For a review, see Vaughan et al., Nature Biotechnology, 16, 535-539, 1998. In one embodiment, only one or more specificity determining residues from any CDR described above are transferred to the human antibody framework instead of the entire CDR (see, e.g., Kashmiri et al., 2005, Methods, 36: 25-34). In one embodiment, only the specificity determining residues from one or more CDRs described above are transferred to the human antibody framework. In another embodiment, only the specificity determining residues from each CDR described above are transferred to the human antibody framework. When grafting CDRs or specificity determining residues, any appropriate acceptor variable region framework sequence may be used, including mouse, primate, and human framework regions, taking into account the species / type of the donor antibody from which the CDRs are derived.
[0075] Suitably, the humanized antibodies of the invention have variable domains comprising human acceptor framework regions and one or more CDRs specifically provided herein. Thus, in one embodiment, a humanized antibody is provided which binds to human CSF-1R, wherein the variable domain comprises a human acceptor framework region and a non-human donor CDR.
[0076] Examples of human frameworks that can be used in the present invention are KOL, NEWM, REI, EU, TUR, TEI, LAY, and POM (Kabat et al., supra). For example, KOL and NEWM can be used for the heavy chain, REI can be used for the light chain, and EU, LAY, and POM can be used for both the heavy and light chains. Alternatively, human germline sequences can be used; these are available at http: / / vbase.mrc-cpe.cam.ac.uk / .
[0077] In the humanized antibodies of the invention, the acceptor heavy and light chains are not necessarily derived from the same antibody and may, if desired, comprise composite chains having framework regions derived from different chains.
[0078] In one embodiment, the human framework comprises 1, 2, 3, or 4 amino acid substitutions, additions or deletions, e.g., 1, 2, 3 or 4 conservative substitutions of donor residues.
[0079] In one embodiment, the sequences used as human frameworks have 80%, 85%, 90%, 95% or greater similarity or identity to the sequences disclosed herein.
[0080] One such suitable framework region for the heavy chain of the humanized antibody of the invention is derived from the human subgroup VH2 sequence 3-1 2-70 plus the JH3 J-region (SEQ ID NO: 33).
[0081] Thus, in one example, a humanized antibody is provided comprising the sequence shown in SEQ ID NO: 4 for CDR-H1, the sequence shown in SEQ ID NO: 5 for CDR-H2, and the sequence shown in SEQ ID NO: 6 for CDR-H3, wherein the heavy chain framework region is derived from human subgroup VH3 sequence 1-3 3-07 plus JH4.
[0082] In one example, the heavy chain variable domain of the antibody comprises the sequence shown in SEQ ID NO:23.
[0083] Suitable framework regions for use in the light chain of the humanized antibodies of the invention are derived from human germline subgroup VK1 2-1-(1)012 plus the JK4 J-region (SEQ ID NO: 31).
[0084] Thus, in one embodiment, a humanized antibody is provided comprising the sequence shown in SEQ ID NO: 1 for CDR-L1, the sequence shown in SEQ ID NO: 2 for CDR-L2, and the sequence shown in SEQ ID NO: 3 for CDR-L3, wherein the light chain framework region is derived from human subgroup VK1 2-1-(1)O12 plus JK4 J-region.
[0085] In one example, the light chain variable domain of the antibody comprises the sequence shown in SEQ ID NO:15.
[0086] In the humanized antibody of the present invention, the framework region does not need to have the same sequence as the framework region of the acceptor antibody. For example, uncommon residues can be changed into residues that are more common to the acceptor chain species or types. Alternatively, the selected residues in the acceptor framework region can be changed so that they correspond to the residues found in the same position in the donor antibody (see Reichmann et al., 1998, Nature, 332:323-324). Such changes should be maintained at the minimum required for the affinity of the donor antibody. The scheme for selecting the residues that may need to be changed in the acceptor framework region is shown in WO91 / 09967.
[0087] Thus, in one example, a humanized antibody is provided, wherein at least the residue at position 78 (Kabat numbering) of the heavy chain variable domain is a donor residue. In one embodiment, residue 78 of the heavy chain variable domain is substituted with alanine.
[0088] Donor residues as used herein refer to residues from a non-human antibody (eg, a murine antibody) that provides the CDRs.
[0089] In one embodiment, a humanized antibody is provided, wherein the heavy chain variable domain does not comprise any donor residues.
[0090] Thus, in one example, a humanized antibody is provided, wherein at least one of the residues at positions 38, 71 and 87 (Kabat numbering) of the light chain variable domain is a donor residue. In one embodiment, one of the residues selected from the residues at positions 38, 71 and 87 (Kabat numbering) of the light chain variable domain is a donor residue. In one embodiment, two of the residues selected from the residues at positions 38, 71 and 87 (Kabat numbering) of the light chain variable domain (e.g., 38 and 71; or 38 and 87; or 71 and 87) are donor residues. In one embodiment, three residues at positions 38, 71 and 87 (Kabat numbering) of the light chain variable domain are donor residues.
[0091] In one embodiment, residue 38 of the light chain variable domain is replaced by lysine. In an alternative embodiment, residue 38 of the light chain variable domain is replaced by glutamine.
[0092] In one embodiment, residue 71 of the light chain variable domain is replaced with tyrosine.
[0093] In one embodiment, residue 87 of the light chain variable domain is replaced with phenylalanine.
[0094] In one embodiment, a humanized antibody is provided, wherein only residue 71 in the light chain variable region is a donor residue, preferably tyrosine.
[0095] In a specific embodiment, the present invention provides an anti-CSF-1R antibody or a binding fragment thereof having a heavy chain comprising the heavy chain variable domain sequence shown in SEQ ID NO:23 and a light chain comprising the light chain variable domain sequence shown in SEQ ID NO:15.
[0096] In other aspects of the present disclosure, an anti-CSF-1R antibody or a binding fragment thereof is provided, which binds to CSF-1R (preferably the extracellular domain of CSF-1R, most preferably the extracellular domain of human CSF-1R), wherein the antibody or binding fragment comprises a light chain variable domain of SEQ ID NO: 15 and a heavy chain variable domain of SEQ ID NO: 23, preferably, wherein the antibody or binding fragment thereof is a monoclonal antibody, an IgG1-IgG2-, IgG4-type antibody, Fab, modified Fab, Fab', modified Fab', F(ab')2, Fv, a single domain antibody (e.g., VH or VL or VHH), scFv, a bivalent, trivalent or tetravalent antibody, a bispecific-scFv, a diabody, a triabody or a tetrabody.
[0097] In one embodiment, the disclosure provides an antibody sequence that is 80% similar or identical to a sequence disclosed herein (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% similar or identical in part or in the entire related sequence). In one embodiment, the related sequence is SEQ ID NO: 15. In one embodiment, the related sequence is SEQ ID NO: 23.
[0098] As used herein, "identity" indicates that at any particular position of the compared sequences, the amino acid residues between the sequences are the same. As used herein, "similarity" indicates that at any particular position of the compared sequences, the amino acid residues between the sequences are of a similar type. For example, leucine can be replaced with isoleucine or valine. Other amino acids that can be commonly replaced with each other include (but are not limited to):
[0099] - phenylalanine, tyrosine and tryptophan (amino acids with aromatic side chains);
[0100] - lysine, arginine and histidine (amino acids with basic side chains);
[0101] - Aspartic acid and glutamic acid (amino acids with acidic side chains);
[0102] - Asparagine and glutamine (amino acids with amide side chains); and
[0103] - Cysteine and methionine (amino acids with sulfur-containing side chains). The degree of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987, Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991, BLAST TM The software is available from NCBI (Altschul, SF et al., 1990, J. Mol. Biol. 215:403-410; Gish, W. & States, DJ 1993, Nature Genet. 3:266-272. Madden, TL et al., 1996, Meth. Enzymol. 266:131-141; Altschul, SF et al., 1997, Nucleic Acids Res. 25:3389-3402; Zhang, J. & Madden, TL 1997, Genome Res. 7:649-656).
[0104] The antibody molecules of the present invention may include complete antibody molecules or binding fragments thereof having full-length heavy and light chains and may be, but are not limited to, Fab, modified Fab, Fab', modified Fab', F(ab')2, Fv, single domain antibodies (e.g., VH or VL or VHH), scFv, bivalent, trivalent or tetravalent antibodies, bispecific-scFv, diabodies, triabodies, tetrabodies and epitope binding fragments of any of the above antibodies (see, e.g., Holliger and Hudson, 2005, Nature Biotech. 23(9): 1126-1136; Adair and Lawson, 2005, Drug Design Reviews-Online 2(3), 209-217). Methods for creating and manufacturing these antibody fragments are well known in the art (see, e.g., Verma et al., 1998, Journal of Immunological Methods, 216: 165-181). Other antibody fragments useful in the present invention include Fab and Fab' fragments described in International Patent Applications WO05 / 003169, WO05 / 003170 and WO05 / 003171. Multivalent antibodies may comprise multiple specificities, such as bispecifics, or may be monospecific (see, for example, WO 92 / 22853, WO05 / 113605, WO2009 / 040562 and WO2010 / 035012).
[0105] As used herein, a binding fragment of an antibody refers to a fragment that is capable of binding an antigen with an affinity that characterizes the fragment as being specific for the antigen.
[0106] In one embodiment, an antibody of the disclosure is provided as a CSF-1R binding antibody fusion protein comprising an immunoglobulin portion (e.g., a Fab or Fab' fragment) and one or two single domain antibodies (dAbs) linked directly or indirectly thereto, e.g., as described in WO2009 / 040562, WO2010 / 035012, WO2011 / 030107, WO2011 / 061492 and WO2011 / 086091, all of which are incorporated herein by reference.
[0107] In one embodiment, the fusion protein comprises two domain antibodies, for example as a variable heavy chain (VH) and a variable light chain (VL) pairing, optionally linked by a disulfide bond.
[0108] In one embodiment, the Fab or Fab' element of the fusion protein has the same or similar specificity as a single domain antibody. In one embodiment, the Fab or Fab' has a different specificity than a single domain antibody, in other words the fusion protein is multivalent. In one embodiment, the multivalent fusion protein according to the invention has an albumin binding site, for example, the VH / VL pair therein provides an albumin binding site.
[0109] In one embodiment, the Fab or Fab' member pairs or single domain antibodies of the fusion protein have the same or similar specificity. In one embodiment, the Fab or Fab' pairs or single domain antibodies have different specificities, in other words, the fusion protein is multivalent. In one embodiment, the multivalent fusion protein of the disclosure has an albumin binding site, for example, the VH / VL pair therein provides an albumin binding site.
[0110] The constant region domain (if present) of the antibody molecule of the present invention can be selected based on the proposed antibody molecule function and the effector function that may be required in particular. For example, the constant region domain can be a human IgA, IgD, IgE, IgG or IgM domain. Specifically, when the antibody molecule is intended for therapeutic use and antibody effector function is required, human IgG constant region domains, particularly human IgG constant region domains of IgG1 and IgG3 isotypes can be used. Alternatively, when the antibody molecule is intended for therapeutic purposes and antibody effector function is not required, IgG2 and IgG4 isotypes can be used.
[0111] In specific embodiments, the antibodies of the invention are IgG2 or IgG4 antibodies.
[0112] It will be appreciated that sequence variants of this constant region domain may also be used. For example, an IgG4 molecule in which the serine at position 241 has been changed to a proline as described in Angal et al., 1993, Molecular Immunology, 1993, 30: 105-108 may be used. Thus, in embodiments in which the antibody is an IgG4 antibody, the antibody may include the mutation S241P.
[0113] It will also be appreciated by those skilled in the art that antibodies may undergo various post-translational modifications. The type and extent of these modifications often depend on the host cell line and culture conditions used to express the antibody. Such modifications may include changes in glycosylation, methionine oxidation, diketopiperazine formation, aspartic acid isomerization, and asparagine deamidation. Common modifications are the absence of carboxyl terminal basic residues (such as lysine or arginine) due to the action of carboxypeptidases (as described in Harris, RJ. Journal of Chromatography 705: 129-134, 1995). Therefore, the C-terminal lysine of the antibody heavy chain may be absent.
[0114] In one embodiment, the antibody heavy chain comprises a CH1 domain, and the antibody light chain comprises a CL domain (κ or λ).
[0115] In one embodiment, the antibody heavy chain comprises a CH1 domain, a CH2 domain, and a CH3 domain, and the antibody light chain comprises a CL domain (κ or λ).
[0116] The present invention provides an antibody having a heavy chain comprising the sequence shown in SEQ ID NO: 27 and a light chain comprising the sequence shown in SEQ ID NO: 19. Also provided is an anti-CSF-1R antibody or binding fragment thereof, wherein the heavy chain and the light chain are at least 80% (preferably 85%, 90%, 95% or 98%) identical or similar to the heavy chain comprising the sequence shown in SEQ ID NO: 27 and the light chain comprising the sequence shown in SEQ ID NO. 19. In one embodiment, the light chain has or consists of the sequence shown in SEQ ID NO: 19 and the heavy chain has or consists of the sequence shown in SEQ ID NO: 27. In another embodiment, the light chain has or consists of the sequence of SEQ ID NO: 19 and the heavy chain has or consists of the sequence of SEQ ID NO: 27, wherein the amino acid lysine at position 453 of SEQ ID NO: 27 is deleted or deleted.
[0117] The present disclosure also provides specific regions or epitopes of human CSF-1R bound by the antibodies provided by the present invention, specifically antibody 969.g2 comprising the heavy chain sequence gH2 (SEQ ID NO: 27) and / or the light chain sequence gL7 (SEQ ID NO: 19).
[0118] This specific region or epitope of the human CSF-1R polypeptide can be identified by any suitable epitope mapping method known in the art in conjunction with any of the antibodies provided herein. Examples of such methods include screening peptides of varying lengths derived from CSF-1R for binding to the antibodies of the invention (e.g., peptides ranging in length from about 5 to 10 (preferably about 7) amino acids), wherein the smallest fragment capable of specifically binding to the antibody contains the sequence of the epitope recognized by the antibody. The CSF-1R peptides can be produced synthetically or by proteolytic digestion of the CSF-1R polypeptide. Peptides that bind to the antibody can be identified, for example, by mass spectrometry. In another example, NMR spectroscopy or X-ray crystallography can be used to identify the epitope bound by the antibodies of the invention. Once identified, if desired, epitope fragments that bind to the antibodies of the invention can be used as immunogens to obtain additional antibodies that bind to the same epitope.
[0119] Biomolecules (such as antibodies or fragments) contain acidic and / or basic functional groups, thereby imparting a net positive or negative charge to the molecule. The amount of "observed" total charge will depend on the absolute amino acid sequence of the entity, the local environment of the charged groups in the 3D structure, and the environmental conditions of the molecule. The isoelectric point (pi) is the pH at which a particular molecule or its solvent can approach the surface without a net charge. In one example, the CSF-1R antibodies and fragments of the invention can be engineered to have an appropriate isoelectric point. This may result in antibodies and / or fragments having more robust properties, particularly suitable solubility and / or stability characteristics and / or improved purification characteristics.
[0120] Thus, in one aspect, the invention provides a humanized CSF-1R antibody that is engineered to have an isoelectric point that is different from that of the original identified antibody. The antibody may be engineered, for example, by substitution of amino acid residues, such as substitution of one or more basic amino acid residues for an acidic amino acid residue. Alternatively, basic amino acid residues may be introduced or acidic amino acid residues may be removed. Alternatively, if the molecule has an unacceptably high pI value, acidic residues may be introduced to lower the pI, as desired. Importantly, when manipulating the pI, care must be taken to retain the desired activity of the antibody or fragment. Thus, in one embodiment, the engineered antibody or fragment has the same or substantially the same activity as the "unmodified" antibody or fragment.
[0121] Programs such as **ExPASY http: / / www.expasy.ch / tools / pi_tool.html and http: / / www.iut-arles.up.univ-mrs.fr / w3bb / d_abim / compo-p.html can be used to predict the isoelectric point of antibodies or fragments.
[0122] It will be appreciated that the affinity of the antibodies provided by the invention may be altered using any suitable method known in the art. Thus, the invention also relates to variants of the antibody molecules of the invention having improved affinity for CSF-1R. Such variants may be obtained by a number of affinity maturation protocols, including mutating CDRs (Yang et al., 1995, J. Mol. Biol., 254:392-403), chain shuffling (Marks et al., 1992, Bio / Technology, 10:779-783), using mutant strains of E. coli (Low et al., 1996, J. Mol. Biol., 250:359-368), DNA shuffling (Patten et al., 1997, Curr. Opin. Biotechnol., 8 :724-733), phage display (Thompson et al., J. Mol. Biol., 256, 77-88, 1996) and sexual PCR (Crameri et al., 1998, Nature, 391 :288-291). These affinity maturation methods are discussed by Vaughan et al. (supra).
[0123] If desired, the antibodies used in the present invention can be conjugated to one or more effector molecules. It will be understood that the effector molecule can include a single effector molecule or two or more such molecules (which are connected to form a single part that can be attached to the antibody of the present invention). When it is desired to obtain an antibody fragment connected to an effector molecule, this can be prepared by standard chemical or recombinant DNA procedures, wherein the antibody fragment is directly or via a coupling agent connected to the effector molecule. The technology for conjugating such effector molecules to antibodies is well known in the art (see Hellstrom et al., Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-53; Thorpe et al., 1982, Immunol. Rev., 62: 119-58 and Dubowchik et al., 1999, Pharmacology and Therapeutics, 83, 67-123). Specific chemical methods include, for example, those described in WO 93 / 06231, WO 92 / 22583, WO 89 / 00195, WO 89 / 01476 and WO 03 / 031581. Alternatively, where the effector molecule is a protein or polypeptide, linkage may be achieved using recombinant DNA procedures such as described in WO 86 / 01533 and EP0392745.
[0124] The term "effector molecule" as used herein includes, for example, anti-tumor agents, drugs, toxins, biologically active proteins, such as enzymes, other antibodies or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof, such as DNA, RNA and fragments thereof, radionuclides, in particular radioiodides, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds detectable by NMR or ESR spectroscopy.
[0125] Examples of effector molecules include cytotoxins or cytotoxic agents, which include any agent that is harmful to (e.g., kills) cells. Examples include combrestatin, dolastatin, epothilone, staurosporine, maytansinoids, spongistatin, rhizoxin, halichondrin, bacillus sporin, hemiasterlins, paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol and puromycin and analogs or homologs thereof.
[0126] Effector molecules also include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil dacarbazine), alkylating agents (e.g., nitrogen mustard, thiotepa, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, anthramycin (AMC), calicheamicin or duocarmycins), and antimitotic agents (e.g., vincristine and vinblastine).
[0127] Other effector molecules may include chelated radionuclides such as 111 In and 90 Y. Lu 177 ,bismuth 213 ,californium 252 ,iridium 192 and tungsten 188 / rhenium 188 ; or drugs such as, but not limited to, alkylphosphorylcholines, topoisomerase I inhibitors, taxanes, and suramin.
[0128] Other effector molecules include proteins, peptides and enzymes. The enzymes of interest include, but are not limited to, proteolytic enzymes, hydrolases, lysates, isomerases, transferases. Proteins, polypeptides and peptides of interest include, but are not limited to, immunoglobulins, toxins such as abrin, ricin A, Pseudomonas exotoxin or diphtheria toxin, proteins such as insulin, tumor necrosis factor, α-interferon, β-interferon, nerve growth factor, platelet-derived growth factor or tissue plasminogen activator, thrombotic agents or anti-angiogenic agents such as angiostatin or endostatin, or biological response modifiers such as lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), nerve growth factor (NGF) or other growth factors and immunoglobulins.
[0129] Other effector molecules may include, for example, detectable substances useful in diagnosis. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radionuclides, positron-emitting metals (for positron emission tomography), and non-radioactive paramagnetic metal ions. For metal ions that can be conjugated to antibodies for use as diagnostic agents, see generally U.S. Pat. No. 4,741,900. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin, and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radionuclides include 125 I. 131 I. 111 In and 99 Tc.
[0130] In another example, the effector molecule can increase the in vivo half-life of the antibody, and / or reduce the immunogenicity of the antibody and / or enhance the delivery of the antibody across the epithelial cell barrier to the immune system. Examples of suitable effector molecules of this type include polymers, albumin, albumin binding proteins or albumin binding compounds, such as those described in WO05 / 117984.
[0131] In one embodiment, the half-life provided by an effector molecule that is independent of CSF-1R is advantageous.
[0132] Generally speaking, where the effector molecule is a polymer, it may be a synthetic or naturally occurring polymer, such as an optionally substituted linear or branched polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, such as a homo- or heteropolysaccharide.
[0133] Specific optional substituents which may be present on the synthetic polymers described above include one or more hydroxyl, methyl or methoxy groups.
[0134] Specific examples of synthetic polymers include optionally substituted linear or branched poly(ethylene glycol), poly(propylene glycol), poly(vinyl alcohol) or derivatives thereof, especially optionally substituted poly(ethylene glycol) such as methoxypoly(ethylene glycol) or derivatives thereof.
[0135] Specific naturally occurring polymers include lactose, amylose, dextran, glycogen or derivatives thereof.
[0136] In one embodiment, the polymer is albumin or a fragment thereof, such as human serum albumin or a fragment thereof.
[0137] As used herein, "derivatives" are intended to include reactive derivatives, e.g., sulfhydryl selective reactive groups such as maleimide, etc. The reactive group may be directly attached to the polymer or attached to the polymer via a linker segment. It will be understood that the residue of such a group may in some cases form part of the product as a linking group between the antibody fragment and the polymer.
[0138] The size of the polymer can be changed as needed, but generally will be in the range of an average molecular weight of 500Da to 50000Da, for example 5000 to 40000Da such as 20000 to 40000Da. The size of the polymer can be selected based on the intended use of the product (e.g., the ability to locate to certain tissues (such as tumors) or extend the circulation half-life) (for review, see Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). Therefore, for example, when the product is intended to leave the circulation and penetrate the tissue (e.g., for the treatment of tumors), it may be advantageous to use a small molecular weight polymer (e.g., a molecular weight of about 5000Da). For applications where the product remains in the circulation, it may be advantageous to use a higher molecular weight polymer (e.g., a molecular weight in the range of 20000Da to 40000Da).
[0139] Suitable polymers include polyalkylene polymers such as poly(ethylene glycol), or in particular methoxypoly(ethylene glycol) or derivatives thereof, and in particular having a molecular weight in the range of about 15000 Da to about 40000 Da.
[0140] In one example, the antibody for the present invention is attached to a poly (ethylene glycol) (PEG) moiety. In a specific example, the antibody is an antibody fragment and the PEG molecule can be attached by any available amino acid side chain or terminal amino acid functional group (e.g., any free amino, imino, sulfhydryl, hydroxyl or carboxyl) located in the antibody fragment. Such amino acids can be naturally present in the antibody fragment or can be engineered into the fragment using a recombinant DNA method (see, e.g., US 5,219,996; US 5,667,425; WO98 / 25971, WO2008 / 038024). In one example, the antibody molecule of the present invention is a modified Fab fragment, wherein the modification is to add one or more amino acids to the C-terminal of its heavy chain to allow the attachment of effector molecules. Suitably, additional amino acids form a modified hinge region containing one or more cysteine residues, to which the effector molecule can be attached. Multiple sites can be used to attach two or more PEG molecules.
[0141] Suitably, the PEG molecule is covalently linked by the sulfhydryl group of at least one cysteine residue in the antibody fragment. Each polymer molecule attached to the modified antibody fragment can be covalently linked to the sulfur atom of the cysteine residue in the fragment. Covalent linkage is generally a disulfide bond or particularly a sulfur-carbon bond. In the case where the sulfhydryl group is used as an attachment point, an appropriately activated effector molecule can be used, such as a sulfhydryl selective derivative such as maleimide and a cysteine derivative. The activated polymer can be used as a starting material in the process of preparing the polymer-modified antibody fragment as described above. The activated polymer can be any polymer containing a sulfhydryl reactive group (such as α-halocarboxylic acid or ester, such as iodoacetamide, imide, such as maleimide, vinyl sulfone or disulfide). Such a starting material can be obtained commercially (for example, from Nektar (formerly Shearwater Polymers Inc.), Huntsville, AL, USA) or conventional chemical methods can be used to prepare from commercially available starting materials. Specific PEG molecules include 2OK methoxy-PEG-amine (available from Nektar, formerly Shearwater; Rapp Polymere; and SunBio) and M-PEG-SPA (available from Nektar, formerly Shearwater).
[0142] In one embodiment, the antibody is a modified Fab fragment, Fab' fragment or diFab, which is PEGylated, i.e. has PEG (poly(ethylene glycol)) covalently attached thereto, for example according to the methods disclosed in EP 0948544 or EP1090037 (see also "Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications", 1992, J. Milton Harris (ed), Plenum Press, New York, "Poly(ethyleneglycol) Chemistry and Biological Applications", 1997, J. Milton Harris and S. Zalipsky (eds), American Chemical Society, Washington DC and "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, M. Aslam and A. Dent, Grove Publishers, New York; Chapman, A. 2002, Advanced Drug Delivery Reviews 2002, 54:531-545). In one example, PEG is attached to the cysteine in the hinge region. In one example, the Fab fragment modified by PEG has a maleimide group covalently attached to a single sulfhydryl group in the hinge region of the modification. Lysine residues can be covalently attached to the maleimide group and a methoxy poly (ethylene glycol) polymer with a molecular weight of about 20,000Da can be attached to each amine group on the lysine residues. Therefore, the total molecular weight of the PEG attached to the Fab fragment can be about 40,000Da.
[0143] Specific PEG molecules include N,N'-bis(methoxypoly(ethylene glycol) MW 20,000) modified lysine 2-[3-(N-maleimido)propionamido]acetamide, also known as PEG2MAL40K (available from Nektar, formerly Shearwater).
[0144] Alternative sources of PEG linkers include NOF, which supplies GL2-400MA3 (wherein m in the following structure is 5) and GL2-400MA (wherein m is 2) and n is about 450:
[0145]
[0146] That is, each PEG is approximately 20,000 Da.
[0147] Thus, in one embodiment PEG is 2,3-bis(methylpolyoxyethylene-oxy)-1-{[3-(6-maleimido-1-oxyhexyl)amino]propoxy}hexane (2-arm branched PEG, -CH2)3NHCO(CH2)5-MAL, Mw 40,000, referred to as SUNBRIGHT GL2-400MA3.
[0148] Further optional PEG effector molecules are of the following types:
[0149]
[0150] In one embodiment, the invention provides an antibody, such as a full length antibody, that is PEGylated (e.g., with a PEG as described herein) via attachment to a cysteine amino acid residue at or about amino acid position 226 of the chain (e.g., amino acid position 226 of the heavy chain (by consecutive numbering)).
[0151] In one embodiment, the disclosure provides a Fab'PEG molecule comprising one or more PEG polymers, eg, 1 or 2 polymers such as a 40 kDa polymer.
[0152] Fab-PEG molecules according to the present disclosure may be particularly advantageous because they have a half-life that is independent of the Fc fragment.
[0153] In one embodiment, the invention provides a scFv conjugated to a polymer such as a PEG molecule, a starch molecule or an albumin molecule.
[0154] In one embodiment, the antibody or fragment is conjugated to a starch molecule, for example to increase half-life.Methods for conjugating starch to proteins are described in US 8,017,739, which is incorporated herein by reference.
[0155] As used herein, a reporter molecule is a molecule capable of being detected, for example, a fluorescent dye, a radioactive label, or other detectable entity.
[0156] The present invention also provides the DNA sequence of the separation of the heavy chain and / or light chain of the antibody molecule of the present invention encoding.Suitably, the heavy chain or light chain of the antibody molecule of the present invention encoding DNA sequence.DNA sequence of the present invention may include synthetic DNA, cDNA, genomic DNA or any combination thereof, for example, produced by chemical treatment.
[0157] The DNA sequence encoding the antibody molecule of the present invention can be obtained by methods well known to those skilled in the art. For example, the DNA sequence encoding part or all of the heavy and light chains of the antibody can be synthesized from a determined DNA sequence or based on the corresponding amino acid sequence as needed.
[0158] DNA encoding the acceptor framework sequence is widely available to those skilled in the art and can be easily synthesized based on its known amino acid sequence.
[0159] Standard techniques of molecular biology can be used to prepare DNA sequences encoding antibody molecules of the present invention. The desired DNA sequence can be synthesized in whole or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques can be appropriately used.
[0160] Examples of suitable DNA sequences are provided in Figure 1 .
[0161] The present invention also relates to a cloning or expression vector comprising one or more DNA sequences of the present invention. Therefore, a cloning or expression vector comprising one or more DNA sequences encoding an antibody of the present invention is provided. In one embodiment, the vector comprises the sequence shown in SEQ ID NO: 28 and / or SEQ ID NO: 20. Suitably, the cloning or expression vector comprises two DNA sequences encoding the light chain and the heavy chain of the antibody molecule of the present invention, respectively (preferably SEQ ID NO: 28 and SEQ ID NO: 20, respectively), and an appropriate signal sequence. In one example, the vector comprises an intergenic sequence between the heavy chain and the light chain (see WO03 / 048208).
[0162] The general methods for constructing vectors, transfection methods and culture methods are well known to those skilled in the art. In this regard, reference is made to "Current Protocols in Molecular Biology", 1999, FM Ausubel (ed), Wiley Interscience, New York and the Maniatis Manual published by Cold Spring Harbor Publishing.
[0163] Also provided is a host cell comprising one or more clones or expression vectors, the clones or expression vectors comprising one or more DNA sequences encoding the antibodies of the present invention.Any suitable host cell / vector system can be used for the expression of the DNA sequence encoding the antibody molecule of the present invention.Bacteria (e.g., Escherichia coli) and other microbial systems can be used, or eukaryotic (e.g., mammalian) host cell expression systems can also be used.Suitable mammalian host cells include CHO, myeloma or hybridoma cells.
[0164] The present invention also provides a method for preparing the antibody molecule of the present invention, which comprises culturing a host cell comprising the vector of the present invention under conditions suitable for causing protein expression from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.
[0165] The antibody molecule may comprise only heavy chain or light chain polypeptides, in which case only the heavy chain or light chain polypeptide coding sequence is required for transfection of the host cell. For the production of products comprising heavy and light chains, two vectors (a first vector encoding light chain polypeptides and a second vector encoding heavy chain polypeptides) can be used to transfect the cell line. Alternatively, a single vector can be used, the vector comprising sequences encoding heavy and light chain polypeptides.
[0166] The antibodies and fragments of the present disclosure are expressed at good levels from host cells. Thus, the properties of the antibodies and / or binding fragments are suitable for commercial scale expression.
[0167] Thus, methods of culturing host cells and expressing antibodies or fragments thereof, isolating antibodies or fragments thereof and optionally purifying them to provide isolated antibodies or fragments are provided. In one embodiment, the method further comprises the step of conjugating an effector molecule to the isolated antibody or fragment, for example, to a PEG polymer, in particular as described herein.
[0168] In one embodiment, a method of purifying an antibody (particularly an antibody or fragment of the invention) is provided, which comprises performing anion exchange chromatography in a non-binding mode such that impurities are retained on the column and the antibody is eluted.
[0169] In one embodiment, purification utilizes affinity capture on a CSF-1R column.
[0170] In one embodiment, purification utilizes cibacron blue or an analog for purification of the albumin fusion or conjugated molecules.
[0171] Suitable ion exchange resins for use in the process include Q.FF resin (supplied by GE-Healthcare). The step may be carried out, for example, at a pH of about 8.
[0172] The method may further include an initial capture step using cation exchange chromatography, for example, at a pH of about 4 to 5 (such as 4.5). The cation exchange chromatography may, for example, use a resin such as CaptoS resin or SP Sepharose FF (supplied by GE-Healthcare). The antibody or fragment may then be eluted from the resin using, for example, an ionic salt solution (such as sodium chloride) at a concentration of 200 mM.
[0173] Thus, the chromatography step may suitably include one or more wash steps.
[0174] The purification method may also comprise one or more filtration steps, such as a diafiltration step.
[0175] Thus in one embodiment, a purified anti-CSF-1R antibody or fragment, e.g. a humanized antibody or fragment, in particular an antibody or fragment of the invention, is provided in a substantially purified form, in particular free or substantially free of endotoxin and / or host cell proteins or DNA.
[0176] Purified form as used hereinabove means at least 90% pure, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% w / w or higher.
[0177] Substantially free of endotoxin generally means an endotoxin content of 1 EU / mg antibody product or less, such as 0.5 or 0.1 EU / mg product.
[0178] Substantially free of host cell proteins or DNA generally means a host cell protein and / or DNA content of suitably 400 μg / mg antibody product or less, such as 100 μg / mg or less, particularly 20 μg / mg.
[0179] The present invention also provides an anti-CSF-1R antibody of the present disclosure for use as a medicament (or a pharmaceutical composition comprising the same).
[0180] The present invention also provides the anti-CSF-1R antibody of the present disclosure (or a pharmaceutical composition comprising the same) for use in treating cancer.
[0181] The present invention also provides use of the anti-CSF-1R antibody of the present disclosure (or a pharmaceutical composition comprising the same) in the preparation of a medicament for treating or preventing cancer.
[0182] The present invention also provides a method of treating a human subject having or at risk of cancer, the method comprising administering to the subject an effective amount of an anti-CSF-1R antibody of the disclosure.
[0183] The antibodies of the present disclosure can be used to treat a cancer selected from the group consisting of breast cancer, prostate cancer, bone cancer, myeloma, colorectal cancer, leukemia, lymphoma, skin cancer (such as melanoma), esophageal cancer, gastric cancer, astrocytic carcinoma, endometrial cancer, cervical cancer, bladder cancer, kidney cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer, and ovarian cancer.
[0184] In one embodiment, the cancer is a metastatic cancer from any of the primary cancers listed above, particularly bone cancer.
[0185] Surprisingly, we have been able to demonstrate that anti-CSF-1R antibodies that inhibit CSF-1R activity are active in treating fibrotic diseases. In particular, we have been able to demonstrate that anti-CSF-1R antibodies are active in an in vivo animal model of pulmonary fibrosis.
[0186] The present invention also provides an anti-CSF-1R antibody of the present disclosure (or a pharmaceutical composition comprising the same) for use in treating a fibrotic disease.
[0187] The present invention also provides use of the anti-CSF-1R antibody of the present disclosure (or a pharmaceutical composition comprising the same) in the preparation of a medicament for treating or preventing a fibrotic disease.
[0188] The present invention also provides a method for treating a human subject having or at risk of a fibrotic disease, the method comprising administering to the subject an effective amount of an anti-CSF-1R antibody of the present disclosure.
[0189] In the present application, the term "fibrotic disease" includes diseases characterized by an abnormal response to wound healing, in which excessive fibrous connective tissue is formed in an organ or tissue. Exemplary fibrotic diseases include, but are not limited to, pulmonary fibrosis such as idiopathic pulmonary fibrosis and cystic fibrosis, renal fibrosis including tubular atrophy and interstitial fibrosis, liver fibrosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloids, myocardial infarction, scleroderma, systemic sclerosis, and arthrofibrosis.
[0190] In one embodiment, the antibodies or fragments of the disclosure are used to treat or prevent cancer or fibrotic diseases.
[0191] The antibodies of the disclosure can be used to treat inflammatory diseases, such as inflammatory arthritis, atherosclerosis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid spondylitis, ankylosing arthritis, arthritis, psoriatic arthritis, rheumatoid arthritis, osteoarthritis, eczema, contact dermatitis, psoriasis, toxic shock syndrome, sepsis, septic shock, endotoxic shock, asthma, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft-versus-host reaction, allograft rejection, multiple sclerosis, muscle degeneration, muscular dystrophy, Alzheimer's disease and stroke.
[0192] The antibodies and fragments of the disclosure may be used therapeutically or prophylactically.
[0193] The antibody molecules of the invention may also be used diagnostically, for example for in vivo diagnosis and imaging of disease states in which CSF-1R is implicated.
[0194] Because the antibodies of the present invention can be used to treat and / or prevent pathological conditions, the present invention also provides a pharmaceutical or diagnostic composition comprising an antibody molecule of the present invention in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. Therefore, the use of the antibodies of the present invention for preparing a medicament is provided. The composition will generally be provided as part of a sterilized pharmaceutical composition that will generally include a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention may additionally include a pharmaceutically acceptable adjuvant.
[0195] The present invention also provides a method for preparing a pharmaceutical or diagnostic composition, which comprises adding and mixing the antibody molecule of the present invention and one or more of a pharmaceutically acceptable excipient, diluent or carrier.
[0196] The antibody molecule can be the only active ingredient in a pharmaceutical or diagnostic composition. Alternatively, the antibody can be administered in combination (e.g., simultaneously, sequentially or separately) with one or more other therapeutically active ingredients. Accordingly, the antibody molecule in a pharmaceutical or diagnostic composition can be accompanied by other active ingredients, including other antibody components, for example, antibodies to the epidermal growth factor receptor family (EGFR, HER-2), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), or non-antibody components such as imatinib, dasatinib, nilotinib, basutinib, gefitinib, erlotinib, temsirolimus, vandetanib vandetanib, vemurafenib, crizotinib, vorinostat, romidepsin, bortezomib, sorafenib, sunitinib, pazopanib, regorafenib, cabozantinib, perfenidone, steroids or other drug molecules (particularly drug molecules whose half-life is independent of CSF-1R binding).
[0197] As used herein, active ingredient refers to an ingredient that has a pharmacological effect, such as a therapeutic effect, at a relevant dosage.
[0198] The pharmaceutical composition suitably comprises a therapeutically effective amount of the antibody of the present invention. As used herein, the term "therapeutically effective amount" refers to the amount of therapeutic agent required to treat, improve or prevent a target disease or condition, or to exhibit a detectable therapeutic, pharmacological or preventive effect. For any antibody, the therapeutically effective amount can first be estimated in a cell culture assay or in an animal model, typically in rodents, rabbits, dogs, pigs or primates. Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration in humans.
[0199] The precise therapeutically effective amount for a human subject will depend on the severity of the disease condition, the subject's general health, the subject's age, weight and sex, diet, time and frequency of administration, drug combination, reaction sensitivity, and tolerance / response to treatment. Such an amount can be determined by routine experimentation and is within the physician's judgment. In general, a therapeutically effective amount will be from 0.01 mg / kg to 500 mg / kg, e.g., 0.1 mg / kg to 200 mg / kg, such as 100 mg / kg.
[0200] The pharmaceutical compositions may conveniently be presented in unit dosage form containing a predetermined amount of the active agent of the invention per dose.
[0201] Therapeutic doses of the antibodies of the disclosure showed no apparent or limited in vivo toxicological effects.
[0202] The compositions may be administered to the patient alone or may be administered in combination (eg, simultaneously, sequentially or separately) with other agents, drugs or hormones.
[0203] In one embodiment, the antibodies or binding fragments of the present disclosure are used together with one or more other cancer treatment options (e.g., chemotherapy, radiotherapy, or surgery). If administered with a chemotherapeutic agent, the antibody may be administered before, after, or simultaneously with the chemotherapeutic agent. Chemotherapeutic treatments that can be used in combination with the provided antigen binding proteins include, but are not limited to, alkylating / DNA damaging agents (e.g., carboplatin, cisplatin), antimetabolites (e.g., capecitabine, gemcitabine, 5-fluorouracil), mitotic inhibitors (e.g., paclitaxel, vincristine).
[0204] The antibodies to be used to treat various inflammatory diseases may be used alone or in combination with various other anti-inflammatory agents.
[0205] The antibodies to be used for the treatment of various fibrotic diseases may be used alone or in combination with various other anti-fibrotic agents. An example of such an agent is Perfedidone.
[0206] The dosage of the antibody molecule of the invention administered depends on the nature of the condition to be treated, the severity of the condition presented and on whether the antibody molecule is used prophylactically or for the treatment of an existing condition.
[0207] The frequency of administration will depend on the half-life of the antibody molecule and the duration of its effect. If the antibody molecule has a short half-life (e.g., 2 to 10 hours), it may be necessary to administer once or more per day. Alternatively, if the antibody molecule has a long half-life (e.g., 2 to 15 days) and / or lasting pharmacodynamic (PD) properties, it may only require administration once per day, once a week, or even once every 1 or 2 months.
[0208] Half-life as used herein refers to the duration of time a molecule is in the circulation, eg, serum / plasma.
[0209] Pharmacodynamics as used herein refers to the characteristic spectrum and in particular duration of the biological effects of a molecule according to the present disclosure.
[0210] The pharmaceutically acceptable carrier itself should not induce the production of antibodies harmful to the individual receiving the composition and should not be toxic. Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid copolymers, and inactive viral particles.
[0211] Pharmaceutically acceptable salts may be used, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates and sulfates, or salts of organic acids such as acetates, propionates, malonates and benzoates.
[0212] Pharmaceutically acceptable carriers in therapeutic compositions may additionally include liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances such as wetting or emulsifying agents or pH buffer substances may be present in such compositions. Such carriers enable pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions for patient ingestion.
[0213] Suitable forms for administration include forms suitable for parenteral administration (e.g., by injection or infusion, such as by rapid injection or continuous infusion). Where the product is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain a formulation agent such as a suspending agent, preservative, stabilizer and / or dispersant. Alternatively, the antibody molecule may be in dry form for reconstitution with an appropriate sterile liquid prior to use.
[0214] After formulation, the compositions of the present invention can be directly administered to a subject. The subject to be treated can be an animal. However, in one or more embodiments, the compositions are adapted for administration to a human subject.
[0215] Suitably, in the formulations of the present disclosure, the pH of the final formulation is not similar to the value of the isoelectric point of the antibody or fragment, for example, a pi of 8-9 or above may be appropriate if the pH of the formulation is 7. While not wishing to be bound by theory, it is believed that this may ultimately provide a final formulation with improved stability, for example, the antibody or fragment remains in solution.
[0216] In one example, a pharmaceutical formulation at a pH ranging from 4.0 to 7.0 comprises: 1 to 200 mg / mL of an antibody of the disclosure, 1 to 100 mM of a buffer, 0.001 to 1% of a surfactant, a) 10 to 500 mM of a stabilizer, b) 10 to 500 mM of a stabilizer and 5 to 500 mM of a tonicity agent, or c) 5 to 500 mM of a tonicity agent.
[0217] The pharmaceutical composition of the present invention can be used by any number of approaches, including but not limited to oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, transdermal, percutaneous (e.g., referring to WO98 / 20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal approaches. Hypodermic syringes can also be used to apply the pharmaceutical composition of the present invention. Generally, therapeutic compositions can be prepared into injections, as liquid solutions or suspensions. Solid forms suitable for dissolving or suspending in liquid vehicles before injection can also be prepared.
[0218] Direct delivery of such compositions will generally be achieved by injection subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of the tissue. The composition may also be administered to the lesion. The dosage regimen may be a single dose regimen or a multiple dose regimen.
[0219] It will be appreciated that the active ingredient in the composition will be an antibody molecule. Therefore, it will be susceptible to degradation in the gastrointestinal tract. Therefore, if the composition is to be administered via a gastrointestinal route, the composition will need to contain an agent that protects the antibody from degradation but releases the antibody after it has been absorbed from the gastrointestinal tract.
[0220] A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Publishing Company, NJ 1991).
[0221] In one embodiment, the formulation is provided as a formulation for topical administration including inhalation.
[0222] Suitable inhalable formulations include inhalable powders, metered aerosols containing propellant gases or inhalable solutions without propellant gases.The inhalable powders containing active substances of the present disclosure may consist solely of the above active substances or of a mixture of the above active substances with physiologically acceptable excipients.
[0223] These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, sucrose, maltose), oligosaccharides and polysaccharides (e.g. dextran), polyols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with each other. Monosaccharides or disaccharides are suitably used, lactose or glucose is used, particularly but not exclusively in the form of its hydrate.
[0224] Particles for deposition in the lung need to have a particle size of less than 10 microns, such as 1 to 9 microns, for example 0.1 to 5 μm, in particular 1 to 5 μm. The particle size of the active ingredient, such as an antibody or fragment, is of primary importance.
[0225] Propellant gases that can be used to prepare inhalable aerosols are known in the art. Suitable propellant gases are selected from hydrocarbons such as n-propane, n-butane or isobutane and halogenated hydrocarbons such as chlorinated and / or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The above-mentioned propellant gases can be used independently or in the form of mixtures thereof.
[0226] Particularly suitable propellant gases are halogenated alkane derivatives selected from TG 11, TG 12, TG 134a and TG 227. Of the above halogenated hydrocarbons, TG134a (1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof are particularly suitable.
[0227] The inhalable aerosol containing the propellant gas may also contain other ingredients, such as co-solvents, stabilizers, surface active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
[0228] The inhalable aerosol containing propellant gas according to the invention may contain up to 5% by weight of active substance. The aerosol according to the invention contains, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1% by weight of active ingredient.
[0229] Alternatively, local administration to the lungs can also be by administering liquid solutions or suspension formulations, for example, using a device such as a nebulizer (e.g., a nebulizer connected to a compressor (e.g., a Pari LC-Jet Plus(R) nebulizer connected to a PariMaster(R) compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.)).
[0230] Antibodies of the present invention can be dispersed in a solvent, for example, delivered in the form of a solution or suspension. It can be suspended in a suitable physiological solution (e.g., saline) or other pharmacologically acceptable solvents or buffered solutions. Buffered solutions as known in the art can be 0.05mg to 0.15mg disodium edetate, 8.0mg to 9.0mg NaCl, 0.15mg to 0.25mg polysorbate, 0.25mg to 0.30mg anhydrous citric acid, and 0.45mg to 0.55mg sodium citrate per 1ml water to achieve a pH of about 4.0 to 5.0. Suspensions can use, for example, lyophilized antibodies.
[0231] Therapeutic suspension or solution formulations may also include one or more excipients. Excipients are well known in the art and include buffers (e.g., citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohol, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. The solution or suspension may be encapsulated in liposomes or biodegradable microspheres. The preparation will typically be provided in a substantially sterile form utilizing a sterilization preparation process.
[0232] This may include preparation and sterilization by filtering the buffered solvent / solution used for the formulation, aseptically suspending the antibody in the sterile buffered solvent solution, and dispensing the formulation into sterile containers by methods well known to those skilled in the art.
[0233] The sprayable formulations of the present disclosure can be provided as single-dose units (eg, sealed plastic containers or vials) packaged in, for example, foil packaging bags. Each vial contains a unit dose in a solvent / solution buffer volume (eg, 2 mL).
[0234] The antibodies disclosed herein may be suitable for delivery by spray.
[0235] It is also envisioned that the antibodies of the invention can be administered using gene therapy. To achieve this, DNA sequences encoding the heavy and light chains of the antibody molecule under the control of appropriate DNA components are introduced into the patient so that the antibody chains are expressed from the DNA sequences and assembled in situ.
[0236] In one embodiment, the disclosure includes the use of antibodies or fragments thereof as reagents or diagnostic agents, for example conjugated to a reporter molecule. Thus, labeled antibodies or fragments of the disclosure are provided. In one aspect, a column comprising an antibody or fragment of the disclosure is provided.
[0237] Thus, provided are anti-CSF-1R antibodies or fragments for use as reagents for:
[0238] 1) Purification of CSF-1R protein (or binding fragment thereof) - which is conjugated to a matrix and used as an affinity column or (in a modified form against CSF-1R) used as a precipitant (e.g. in a form modified with a domain recognized by another molecule (which may be modified)), which is optionally precipitated by an anti-Fc agent
[0239] 2) Detection and / or quantification of CSF-1R on or in living or fixed cells (cells in vitro or in tissue or cell sections). Uses for this may include quantification of CSF-1R as a biomarker to follow up the effects of anti-CSF-1R treatment. For these purposes, the candidates may be used in modified form (e.g., by adding another moiety, as a gene fusion protein or chemical conjugate, such as adding a reporter molecule, e.g., a fluorescent label for detection purposes).
[0240] 3) Purify or sort cells carrying CSF-1R labeled by binding to the candidate modified as exemplified in (1) and (2).
[0241] In the context of this specification, comprising means including.
[0242] Where technically appropriate, embodiments of the invention may be combined.
[0243] Embodiments are described herein as comprising certain features / elements. The disclosure also extends to separate embodiments consisting of or consisting essentially of said features / elements.
[0244] Technical references such as patents and applications are incorporated herein by reference.
[0245] Any embodiment specifically and explicitly described herein may, alone or in combination with one or more other embodiments, constitute the basis for a waiver. BRIEF DESCRIPTION OF THE DRAWINGS
[0246] The present invention is further described by way of illustration only in the following examples, which refer to the following drawings:
[0247] Figures 1A to 1F Certain amino acid and polynucleotide sequences are shown.
[0248] Figures 2A to 2B Shows an alignment of some sequences.
[0249] Figure 3 The sequence of the human CSF-1R extracellular domain encoded by the polynucleotide used to transfect cells and express the protein on the cell surface is shown. These cells are then used to immunize a host animal.
[0250] Figure 4 Inhibition of CSF-1 binding to THP-1 cells by antibody Ab969 was shown.
[0251] Figure 5a The inhibition of CSF-1 driven survival and proliferation of primary human monocytes by antibody Ab969 was shown.
[0252] Figure 5b The inhibition of IL-34-driven survival and proliferation of primary human monocytes by antibody Ab969 was shown.
[0253] Figure 6 Inhibition of CSF-1 driven survival and proliferation of primary murine monocytes by antibody Ab535 was shown.
[0254] Figure 7Shown are the levels of cell surface CSF-1R on THP-1 cells incubated with Ab969, human CSF-1 and isotype controls.
[0255] Figure 8 Shown are the relative levels of cell surface CSF-1R on THP-1 cells treated with Ab969 compared to isotype control.
[0256] Fig. 9 Shown are the levels of cell surface CSF-1R on RAW264.7 cells incubated with Ab535, CSF-1 and isotype control.
[0257] Fig.10 Shown are the relative levels of cell surface CSF-1R on RAW264.7 cells treated with Ab535 compared to isotype control.
[0258] Fig.11 Shown are the levels of CSF-1R phosphorylation on HEK293F cells transfected with CSF-1R after stimulation with CSF-1 or treatment with Ab969.
[0259] Fig.12 Shown are the levels of MCP-1 secretion by primary human monocytes when incubated with Ab969 and with CSF-1.
[0260] Fig.13 The effect of inhibiting CSF-1 mediated monocyte survival by humanized antibody 969.g5 compared to chimeric Ab969.g0 is shown.
[0261] Fig.14 The effect of inhibiting CSF-1 mediated monocyte survival by various humanized antibody grafts of Ab969 was shown.
[0262] Fig.15a Shown are the concentrations of CSF-1 in serum samples collected from cynomolgus monkeys treated with a single intravenous dose of 7 mg / kg Ab969.g2.
[0263] Fig.15b Shown are the concentrations of CSF-1 in serum samples collected from cynomolgus monkeys treated with a single intravenous dose of 1.5 mg / kg Ab969.g2.
[0264] Fig.15c The effects of antibody Ab969.g2 administered to cynomolgus monkeys at doses of 7 mg / kg and 1.5 mg / kg on circulating atypical monocytes at different time points are shown.
[0265] Fig.16The anti-tumor effect of antibody Ab535 in immunodeficient nude mice bearing subcutaneous transplants of the human breast cancer xenograft MCF-7 is shown relative to a control antibody, a positive control and a vehicle control.
[0266] Fig.17 The anti-tumor efficacy of antibody Ab535 in the orthotopic prostate cancer model PC-3 is shown relative to a control antibody, a positive control, and a vehicle control.
[0267] Fig.18a Shown are the effects of Ab535 treatment on BALF collagen concentrations compared to isotype control in bleomycin-induced lung fibrosis.
[0268] Fig.18b Shown are the effects of Ab535 treatment of bleomycin-induced lung fibrosis on fibrotic pathology of lung samples measured by Ehrlich score compared to isotype control.
[0269] Fig.18c Shown is the effect of Ab535 treatment on serum albumin concentrations in bleomycin-induced lung fibrosis compared to isotype control.
[0270] Fig.18d The number of macrophages in BAL fluid from mice studied for bleomycin-induced pulmonary fibrosis and shows that Ab535 treatment of bleomycin-induced pulmonary fibrosis resulted in a reduction in the number of macrophages in BAL fluid compared to isotype control treated animals. Data are shown as mean ± SEM; * indicates significant difference from saline isotype; # indicates significant difference from bleomycin treated mice administered with isotype control antibody (p < 0.05)
[0271] Fig.19 Representative images of histopathological analysis of lungs from saline control, bleomycin + isotype control, and bleomycin + Ab535 treated animals are shown.
[0272] Fig.20a Shown are the effects of Ab535 treatment of ADA-deficient mice with induced lung fibrosis on BALF collagen concentrations compared to treatment with isotype control.
[0273] Fig.20b Shown is the effect of Ab535 treatment of ADA-deficient mice with induced lung fibrosis on fibrotic pathology of lung samples measured by Ehrlich score compared to treatment with isotype control.
[0274] Fig.20c Shown are the effects of Ab535 treatment of ADA-deficient mice with induced lung fibrosis on BALF collagen concentrations compared to treatment with isotype control.
[0275] Fig.20d The numbers of macrophages in BAL fluid from mice with an ADA-deficient model of pulmonary fibrosis are shown and Ab535 treatment of ADA-deficient mice with induced pulmonary fibrosis results in a decrease in the number of macrophages in BAL fluid.
[0276] Fig.21 Representative images of histopathological analysis of lungs from normal mice (ADA+) and ADA-deficient mice with induced pulmonary fibrosis (ADA-) treated with isotype control or Ab535 are shown. Example
[0277] Example 1 - Generation of anti-CSF-1R antibodies
[0278] Immunizations:
[0279] Female Sprague Dawley rats were immunized with syngeneic RFL6 rat fibroblasts that had been transiently transfected with a vector expressing the human CSF-1R ectodomain linked to a glycosylated phosphatidyl-inositol (GPI) anchor. Figure 3 SEQ ID NO: 39 is shown, which is the human CSF-1R extracellular domain sequence used for immunization of rats.
[0280] Rats received 3-9 × 10 6 Five subcutaneous immunizations of transfected cells were performed. Complete Freund's adjuvant (50% in PBS) was injected adjacent to the first cell immunization. Two weeks after the last immunization, peripheral blood mononuclear cells (PBMC) and spleen were harvested.
[0281] Primary screening of antibody supernatants
[0282] Antibody supernatants were first screened for their ability to bind to human CSF-1R expressed on transfected HEK293 cells by fluorescence microvolume assay technology (FMAT).
[0283] Approximately 1000 wells with anti-CSF-1R reactivity were identified in the primary FMAT screen of 600 × 96-well plates. A total of approximately 3 × 10 8 B cells (rat spleen cells).
[0284] Secondary screening of antibody supernatants
[0285] A medium throughput assay has been designed to identify FMAT-positive wells containing neutralizing anti-CSF-1R activity (i.e., antibodies that have the ability to prevent human CSF-1 from binding to the human CSF-1R receptor). Antibody supernatants were incubated with THP-1 cells expressing CSF-1R prior to incubation with human CSF-1. The level of CSF-1 bound to THP-1 cells was measured by flow cytometry using an anti-CSF-1 polyclonal antibody. An irrelevant antibody supernatant was used as a negative control.
[0286] The secondary screen was applied to supernatants from 779 antibody wells and 88 of these wells exhibited detectable CSF-1 blocking activity.
[0287] Tertiary screening of antibody supernatants
[0288] Antibody supernatants that had shown neutralizing activity in the secondary screen were tested for their ability to block CSF-1-dependent survival of primary human monocytes. Monocytes were purified from human blood and 1×10 cells were incubated with each antibody supernatant in the presence of 20 ng / ml human CSF-1. 4 After 72 hours of incubation, the number of viable monocytes was measured by CellTiter Glo assay.
[0289] Supernatants from 59 of the antibody wells identified in the secondary screen were applied to the tertiary screen and 18 wells exhibited the ability to reduce CSF-1 -mediated monocyte survival.
[0290] Cloning of antibody variable regions and re-analysis of blocking activity
[0291] Variable region (V-region) cloning was attempted from these 18 antibody wells to confirm CSF-1 neutralizing activity. Heavy and light chain immunoglobulin V-regions were amplified by RT-PCR using primers specific for rat antibody constant regions and a redundant primer set annealing to a sequence encoding a rat immunoglobulin leader peptide. V-region genes were recovered from 14 antibodies and cloned into heavy and light chain human IgG4 expression vectors.
[0292] The antibody-vector pairs were transiently transfected into HEK293F cells and the conditioned media were tested for CSF-1 neutralizing activity on THP-1 cells (as described above). Nine of the antibodies had the ability to partially or completely inhibit CSF-1 binding compared to control conditioned media.
[0293] Sequence analysis of nine neutralizing anti-CSF-1R antibodies
[0294] Nine neutralizing antibodies were sequenced to assess sequence diversity. All nine antibodies were unique. These antibodies were cloned and expressed for further characterization.
[0295] Example 2 - In vitro properties of anti-human CSF-1R chimeric Ab969 and anti-mouse CSF-1R Ab535
[0296] i) Expression of chimeric Ab969
[0297] The variable regions of the nine neutralizing antibodies identified in Example 1 were cloned into separate heavy and light chain expression vectors and expressed as full-length human IgG4 antibodies.
[0298] The VH gene was cloned into the vector pVhg4FL (V19H) containing DNA encoding the native leader sequence and the human gamma-4 heavy chain constant region with the hinge stabilizing mutation S241P. The VL gene (κ) was cloned into the vector pKH10.1 (V4L) containing DNA encoding the native leader sequence and the human kappa chain constant region (Km3 allotype).
[0299] Antibodies were expressed by transient co-transfection of matched heavy and light chain vector pairs into CHO-K1 cells. Antibody purification in PBS pH 7.4 was performed such that the concentration of aggregates in the final preparation was less than 1%.
[0300] The group of nine antibodies includes the antibody designated as antibody 969. The chimeric antibody comprising rat variable regions and human gamma-4 heavy chain constant regions and human kappa chain constant regions is referred to as antibody 969 or antibody 969cHcL or antibody 969.g0 in the following examples.
[0301] ii) Ligand blocking assay
[0302] The ability of each of these nine antibodies to inhibit the binding of CSF-1 to THP-1 cells was evaluated by flow cytometry. THP-1 cells were incubated with 0.5, 0.125, 0.031, 0.0078 and 0.00195 μg / ml of each antibody for 30 minutes. An unrelated IgG4 antibody served as an isotype control. After washing, the cells were incubated with 0.5 μg / ml human CSF-1 for 30 minutes. After further washing, the bound CSF-1 was detected by continuous incubation with biotinylated anti-CSF-1 antibody and Alexa488-conjugated streptavidin. The ligand bound to the receptor was measured by flow cytometry and the median fluorescence intensity (MFI) was plotted.
[0303] This assay identified four antibodies (including Ab969) that were superior to the remaining antibodies tested, demonstrating complete inhibition of CSF-1 binding at a concentration of 31.3 ng / ml. The results for Ab969 are shown in Figure 4 middle.
[0304] iii) CSF-1- and IL-34-mediated inhibition of monocyte survival
[0305] Anti-human CSF-1R:
[0306] Purified anti-human CSF-1R antibodies were tested for their ability to inhibit CSF-1 and IL-34 driven survival and proliferation of primary human monocytes. In each assay, mitogens (CSF-1 or IL-34) were used at concentrations that provided maximal stimulation of monocytes.
[0307] Human PBMCs were prepared from fresh human whole blood on a Ficoll gradient and monocytes were purified by negative selection. Monocytes were incubated with 0.25 μg / ml antibody and 20 ng / ml CSF-1 for 72 hours and the relative number of viable cells was determined using the CellTiter Glo assay. Luminescence readouts correlated with the number of viable cells. Results are shown in Figure 5a middle.
[0308] Human PBMCs were prepared from fresh human whole blood on a Ficoll gradient and monocytes were purified by negative selection. Monocytes were incubated with 0.25 μg / ml antibody and 20 ng / ml IL-34 for 72 hours and the relative number of viable cells was determined using CellTiter Glo analysis. Luminescence readouts correlated with the number of viable cells. Results are shown in Figure 5b middle.
[0309] The four antibodies (including Ab969) showed significant differences in CSF-1 ( Figure 5a ) and IL-34( Figure 5b ) stimulation, consistent with its ligand blocking activity.
[0310] Anti-mouse CSF-1R:
[0311] Purification of primary murine CD11b from mouse spleen + Monocytes. The monocytes were then incubated for 24 hours under titration of mouse CSF-1 (mCSF-1). The release of MCP-1 into the cell culture medium was measured by ELISA and the dose-dependent release of MCP-1 by mCSF-1 was confirmed. In a separate group of this study, 10 μg / ml anti-mouse CSF-1 RAb535 was added along with the mCSF-1 titration. Ab535 completely inhibited the release of MCP-1 at all concentrations of CSF-1 tested ( Figure 6 ).
[0312] The MCP-1 release assay was performed using primary mouse monocytes at a constant CSF-1 concentration of 100 ng / ml and titration of Ab535. Dose-dependent inhibition of MCP-1 release was confirmed and the IC50 The average IC of Ab535 from two independent experiments 50 It was measured to be 8.08ng / ml.
[0313] Conclusion: Treatment of murine monocytes with CSF-1 resulted in a dose-dependent release of MCP-1, which was completely inhibited by treatment with 10 μg / ml Ab535. Ab535 inhibited CSF-1-driven MCP-1 release from murine monocytes in a dose-dependent manner, with an average IC 50 The IC 50 The IC values shown by anti-human CSF-1R antibody 50 The values are similar.
[0314] iv) Affinity
[0315] The ability of the antibodies to bind CSF-1R was tested in a BIAcore assay by measuring the binding kinetics against purified recombinant CSF-1R / Fc fusion protein.
[0316] The assay format was capture of anti-CSF-1R antibodies by immobilized anti-human IgG, F(ab')2 followed by titration of hCSF-1R / Fc on the capture surface. BIA (Biamolecular Interaction Analysis) was performed using a BIAcore 3000 (GE Healthcare Bio-Sciences AB). All experiments were performed at 25°C. Specific Affinipure F(ab')2 fragment goat anti-human IgG, F(ab')2 fragment (Jackson ImmunoResearch) was immobilized on a CM5 Sensor Chip (GE Healthcare Bio-Sciences AB) via amine coupling chemistry to a level of ~5000 response units (RU). HBS-EP buffer (10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20, GE Healthcare Bio-Sciences AB) was used as running buffer with a flow rate of 10 μl / min. Injection of anti-CSF-1R antibody was performed to give a capture level of approximately 100 RU on immobilized anti-human IgG, F(ab)2.
[0317] Recombinant human CSF-1R / Fc (R&D Systems) was passed over the captured anti-CSF-1R antibody at 5 nM at a flow rate of 30 ul / min for 5 min, followed by an increase in flow rate to 100 ul / min for 30 min during the dissociation phase. Injections at 5 nM were performed twice along with the corresponding buffer controls. These sensorgrams were used to generate the off-rates. Recombinant human CSF-1R / Fc was titrated over the captured anti-CSF-1R antibody from 2.5 nM at a flow rate of 30 ul / min for 5 min, followed by a 10 min dissociation phase. These sensorgrams were used to generate the on-rates. The surface was regenerated by a 10 ul injection of 40 mM HCl followed by a 5 ul injection of 10 mM NaOH at a flow rate of 10 ul / min. Double reference background subtracted binding curves were analyzed using BIA Evaluation Software (version 4.1) following standard procedures. Kinetic parameters were determined from the fitting algorithm.
[0318] Three of the four tested antibodies exhibited affinities (K < 10 pM). D ). This was advantageously compared to the anti-murine CSF-1R parallel reagent Ab535. The results for Ab969 and Ab553 are shown in Table 1.
[0319] Table 1:
[0320]
[0321] The affinity of the antibodies was also measured by a cell-based assay using THP-1 cells. The antibodies were directly labeled using Alexa-488 fluorescent dye and the affinity was measured by quantitative flow cytometry. Additional BIAcore analysis confirmed that fluorescent conjugation of the antibodies did not alter the affinity for recombinant CSF-1R protein. The results are shown in Table 2.
[0322] The absolute affinity values obtained by these two methods are different and this difference is often observed when comparing these two systems. However, the cell-based method confirmed that the antibody binds to CSF-1R with high affinity.
[0323] Table 2
[0324]
[0325] v) Inhibition of CSF-1 binding (IC 50 )
[0326] The four antibodies were analyzed by measuring their relative potency in inhibiting the binding of CSF-1 to THP-1 cells. All four antibodies exhibited potent inhibition of CSF-1 binding in this assay format, IC 50 The value was less than 5 ng / ml (~30 pM).
[0327] Table 3
[0328] Antibody <![CDATA[Average IC 50 ± S.D. (ng / ml)]]> Ab969 2.89±1.22
[0329] vi) Antibody cross-reactivity
[0330] The four antibodies were tested for cross-reactivity with rhesus, cynomolgus and canine full-length CSF-1R. In addition to human CSF-1R, all four antibodies also bound to rhesus and cynomolgus CSF-1R, showing significant binding significantly above the isotype control levels.
[0331] Table 4
[0332]
[0333] vii) CSF-1R internalization
[0334] Ab969:
[0335] THP-1 cells were incubated with Ab969 for 0, 0.5, 2, 4, 24, and 48 hours. Human CSF-1 and isotype controls were also used to treat cells, serving as positive and negative controls, respectively. At each time point, the level of cell surface CSF-1R was measured by flow cytometry ( Figure 7 The relative levels of cell surface CSF-1R on cells treated with Ab969 relative to the isotype control were calculated and displayed in Figure 8 middle.
[0336] Treatment of THP-1 cells with recombinant CSF-1 results in a rapid and sustained decrease in cell surface CSF-1R levels; the natural ligand binds to its cognate receptor and drives internalization of the ligand-receptor complex.
[0337] THP-1 cells treated with Ab969 exhibited higher levels of cell surface CSF-1R expression over the entire 48 hour time course compared to untreated and isotype control treated THP-1 cells. This data strongly suggests that Ab969 treatment of THP-1 cells does not result in internalization of cell surface expressed hCSF-1R up to 48 hours after treatment.
[0338] Over time, cell surface expression of CSF-1R increased significantly on both untreated and treated THP-1 cells, except for cells treated with CSF-1. This may be due to changes in expression during cell growth over the 48 hour period of the experiment and could potentially be a stress response.
[0339] To provide further evidence that Ab969 does not enhance receptor internalization, and also to exclude the possibility that the THP-1 cell line is not physiologically relevant, primary human monocytes were also used in the internalization assay. The data from this assay also demonstrated that Ab969 does not cause rapid internalization of cell surface CSF-1R on healthy primary human monocytes.
[0340] Ab535:
[0341] The mouse leukemic monocyte / macrophage cell line RAW264.7 expresses high levels of murine CSF-1R (mCSF-1R) and represents an appropriate cell-based system for testing whether the anti-murine CSF-1R antibody Ab535 can cause receptor internalization.
[0342] RAW264.7 cells were incubated with Ab535 for 0, 0.5, 2, 4, 24, and 48 hours. Cells were also treated with human CSF-1 and isotype controls as positive and negative controls, respectively. At each time point, the level of cell surface CSF-1R was measured by flow cytometry ( Fig. 9 The relative levels of cell surface CSF-1R relative to the isotype control were calculated and displayed in Fig.10 middle.
[0343] The data show that treatment of THP-1 cells with recombinant CSF-1 results in a rapid and sustained decrease in cell surface CSF-1R levels.
[0344] A significant reduction in cell surface mCSF-1R levels was observed on RAW264.7 cells treated with human CSF-1 for 2 hours relative to untreated and isotype control treated cells. This reduction was maintained throughout the 48 hour study. This confirms that human CSF-1 causes mCSF-1R internalization and validates the experimental system for monitoring receptor internalization.
[0345] RAW264.7 cells treated with Ab535 exhibited similar levels of cell surface mCSF-1R over the entire 48 hour time course compared to untreated and isotype control treated cells. Because antibody-mediated receptor internalization is expected to occur within this time frame, this data strongly suggests that Ab535 does not trigger mCSF-1R internalization.
[0346] To provide further evidence that Ab535 does not enhance receptor internalization, primary murine CD11b + Monocyte-Macrophages. These results also demonstrate that treatment of mouse monocyte-macrophages with Ab535 does not result in internalization of cell surface expressed mCSF-1R up to 24 hours after treatment.
[0347] viii) CSF1-R activation
[0348] CSF-1 binds to CSF-1R, resulting in the formation of receptor dimers, which triggers rapid receptor phosphorylation by bringing the kinase domains into close proximity. This subsequently leads to receptor internalization and activation of several well-characterized signaling pathways, including the Ras-MAPK pathway. It is possible that anti-CSF-1R antibodies may cause receptor clustering and trigger downstream signaling cascades. This may be an undesirable property of an antibody that should inhibit receptor signaling, therefore, two independent in vitro assay formats were used to test the receptor agonism of Ab969.
[0349] In the first assay format, antibodies were incubated with cells transfected with human full-length CSF-1R and downstream signaling molecules as well as phosphorylation of the receptor were monitored by Western blotting.
[0350] The THP-1 cell line represents a starting point for monitoring the activation state of CSF-1R. However, the expression level of CSF-1R in this cell line is quite low and difficult to perform biochemical analysis. Therefore, the experimental system was designed to robustly detect the level of CSF-1R phosphorylation. Phosphorylation of CSF-1R can be detected on two tyrosine residues, Y723 and Y809. In addition, phosphorylation of p44 / 42MAPK (Erk1 / 2) on T202 and Y204 was measured as an independent readout of CSF-1R activity. In all experiments, stimulation with CSF-1 was included as a positive control.
[0351] HEK293F cells were transfected with a plasmid vector expressing full-length CSF-1R. After incubation for 24 hours under serum-free conditions, cells were stimulated using 100 μg / ml to 0.001 μg / ml titration of Ab969.g0 for 5 minutes. Cells were also treated with 500 ng / ml recombinant CSF-1 to provide a positive control. Untreated cells were included as negative controls. Protein lysates from treated and untreated cells were separated by SDS-polyacrylamide electrophoresis and blotted onto nitrocellulose. Western immunoblotting was performed using antibodies against phosphorylated-Y723 CSF-1R (Cell Signaling Technology #3151), phosphorylated-Y809 (Cell Signaling Technology #3154), total CSF-1R (Cell Signaling Technology #3152) and phosphorylated-ERK 1 / 2 (p44 / 42 MAPK) (Cell Signaling Technology #5301).
[0352] Unstimulated CSF-1R transfected HEK293F cells exhibited low basal levels of CSF-1R phosphorylation. Stimulation of cells with CSF-1 resulted in CSF-1R phosphorylation levels on residues Y723 and Y809, which could be readily observed by Western blot analysis ( Fig.11 ). There was also a significant stimulation of ERK 1 / 2 phosphorylation after CSF-1 treatment. Treatment of transfected HEK293F cells with antibody Ab969.g0 did not stimulate phosphorylation of CSF-1R or enhance ERK1 / 2 activation.
[0353] In a second assay, antibody Ab969 (monomeric and cross-linked) was incubated with primary human monocytes and MCP-1 secretion was used as a marker of CSF-1R activation. CSF-1 treatment of human monocytes results in their release of monocyte chemoattractant protein-1 (MCP-1). If anti-CSF-1R antibodies have the ability to activate CSF-1R receptors on monocytes, the release of MCP-1 would be expected to occur.
[0354] The previously described biochemical assay used only monomeric anti-CSF-1R antibodies. However, it is possible that cross-linked IgG1 would have an enhanced ability to bring CSF-1R molecules into close proximity and trigger tyrosine phosphorylation and downstream signaling. To assess this, the MCP-1 assay was also performed using Ab969.g0 that had been cross-linked to an anti-human Fc antibody.
[0355] Human monocytes can be prepared from human whole blood as follows: 60 to 100 ml of human whole blood is collected in a BD Vacutainer 10 ml Lithium Heparin 171 IU tube. The blood is distributed to 3-4 Leucosep Ficoll tubes (Greiner Bio-One) and filled with PBS. The tube is centrifuged at 1000 g, 20 ° C for 10 minutes without interruption to collect the PBMC layer. The cells are precipitated and then positively selected human CD14 beads (Miltenyi Biotec 130-050-201) are used to separate monocytes according to the manufacturer's protocol. Antibody Ab969.g0 is cross-linked by adding goat anti-human IgG Fc antibody (R&D Systems G-102-C) with a 2: 1 Ab969.g0:Fc ratio. In the presence of a dose titration of antibody Ab969.g0 or cross-linked Ab969.g0 (half-log serial dilutions, including 16 concentrations, with a maximum concentration of 10 μg / ml), monocytes were seeded in culture medium at 20,000 cells / well. Control wells did not contain antibody in the presence and absence of 100 ng / ml CSF-1 and in the presence and absence of anti-human Fc antibodies (the same concentration as that present in the highest concentration of antibody Ab969.g0 (5 μg / ml)). The cells were incubated for 24 hours, the plates were centrifuged to precipitate the cells, and the supernatant was collected. Secreted MCP-1 was measured by MSD (K151AYB-2) according to the manufacturer's protocol.
[0356] The results from the experiment are shown in Fig.12 No increase in MCP-1 levels was detected for any Ab969.g0 treatment, either in monomeric or cross-linked form; the concentration of MCP-1 in the culture medium of treated cells was the same as that of untreated cells. As expected, cells treated with CSF-1 resulted in a significant and reproducible increase in MCP-1 levels.
[0357] Example 3 - Humanization of Antibody 969 and Selection of Humanized Grafts
[0358] Four anti-CSF-1R antibodies were selected for humanization based on their affinities and properties measured in Example 2.
[0359] i) Generation of humanized grafts
[0360] Antibodies 969 and 970 were humanized by grafting CDRs from rat antibody V regions onto human germline antibody V region frameworks.
[0361] The CDRs grafted from the donor to the acceptor sequence were as defined by Kabat (Kabat et al., 1987) with the exception of CDR-H1 where the combined Chothia / Kabat definition was used (see Adair et al., 1991 Humanised antibodies. WO 91 / 09967).
[0362] The human V region 2-1-(1)012+JK4 J-region (V BASE, http: / / vbase.mrc-cpe.cam.ac.uk / ) was selected as the acceptor for the light chain CDRs. The human V region VH2 3-1 2-70+JH3 J region (V BASE, http: / / vbase.mrc-cpe.cam.ac.uk / ) was selected as the acceptor for the heavy chain CDRs.
[0363] Many framework residues from the rat V region were retained in the humanized sequence, as shown in Table 1.
[0364] An automated synthetic approach was used to design and construct genes encoding the initial humanized light and heavy chain V region sequences (named gL1 and gH1, respectively). Additional variants of the light and heavy chain V regions were created by modifying the gL1 and gH1 genes with oligonucleotide-directed mutagenesis.
[0365] The VK genes (gL1 to gL9) were cloned into the human light chain expression vector pKH10.1 containing DNA encoding the human kappa chain constant region (Km3 allotype). The VH genes (gH1 and gH2) were cloned into the human gamma-4 heavy chain expression vector pVhγ4P FL containing DNA encoding the human gamma-4 heavy chain constant region with the hinge stabilizing mutation S241P (Angal et al., 1993, Mol Immunol. 30: 105-8). Different combinations of plasmids encoding variant light and heavy chains were co-transfected into HEK293F, resulting in the expression of humanized recombinant 969 antibodies.
[0366] The other three anti-CSF-1R antibodies were also humanized by providing conservative grafts containing a number of donor residues predicted to be important in both the heavy and light chains as well as fully humanized grafts containing no donor residues.
[0367] ii) Affinity of humanized antibodies
[0368] Each humanized graft was evaluated for (i) binding affinity to human CSF-1R as measured by BIAcore and (ii) melting temperature (Tm) as measured by ThermoFluor analysis relative to the parental chimeric antibody. Melting temperature is believed to provide an early indication of the stability of the antibody molecule, with unstable antibodies typically exhibiting a Tm of less than 75.0°C.
[0369] The grafts representing the humanization stage of Ab969 are shown in Table 5. Table 5 also shows the chimeric antibody of Ab696 (969cHcL). The conservative graft (969gH1gL1) exhibited an affinity constant (K D ), therefore, there was no significant loss in affinity compared to the chimeric rat antibody (969cHcL). The Tm of the 969gH1gL1 conservative graft was 78.8°C and thus above the threshold of 75.0°C. The substitution of the A78 donor residue for V78 in the heavy chain to generate 969gH2gL1 did not reduce the antibody affinity (K D =2.3 pM). After the K38, Y71 and F87 donor residues were replaced stepwise to Q38, F71 and Y87, respectively, no affinity changes were observed. The final humanized graft 969gH2gL8 without the donor residues exhibited similar affinity to the parental chimeric antibody (4.1 pM).
[0370] Table 5
[0371]
[0372] Ab969 has a potential DG isomerization motif at the junction of CDR-L2 and the framework. The DG site aspartic acid residue in the 969gH2gL7 and 969gH2gL8 grafts was mutated to serine to provide an inactive SG sequence. Affinity for CSF-1R was measured by BIAcore and no apparent loss of affinity was detected (Table 6). In addition, the final 969H2gL7 (SG) and 969gH2gL8 (SG) grafts retained high Tm of 80.5°C and 79.9°C, respectively.
[0373] Table 6
[0374]
[0375] Ab969he humanization of another anti-CSF-1R antibody Ab970 produced antibodies with comparable affinity (K D ) and a fully humanized antibody (absence of rat donor residues) with an initial predicted Tm that gave the stability of the molecule. The fully humanized form of Ab969 (969gH2gL8 SG) was renamed Ab969.g5. Hereafter, the chimeric form of Ab969 will be referred to as Ab969.g0.
[0376] BIAcore analysis was again used to measure the affinity of purified chimeric and humanized grafts of Ab969 antibody to recombinant CSF-1R. Previous BIAcore experiments performed during the humanization process were performed using crude cell supernatant instead of purified antibody. A slight decrease in affinity was detected, K D The values increased from approximately 4 pM to 5 pM.
[0377] Table 7
[0378]
[0379] Iii) Inhibition of CSF-1-mediated monocyte survival by Ab969.g0 and Ab969.g5 CSF-1 is essential for the activation and survival of cultured monocytes; if CSF-1 is removed, monocytes rapidly undergo apoptosis. An assay was designed using MCP-1 (monocyte chemoattractant protein-1; also known as CCL2, chemokine CC motif ligand 2) as a readout. After CSF-1 stimulation, human monocytes secrete MCP-1, which can be detected by ELISA in the cell supernatant, usually at 24 hours after stimulation. Inhibition of CSF-1R signaling by blocking CSF-1-bound antibodies leads to a reduction in MCP-1 secretion.
[0380] Human PBMCs were prepared from fresh human whole blood on a Ficoll gradient and CD14 was purified by positive selection + Monocytes. Total 2×10 4 Mononuclear cells were incubated for 24 hours with half-log serial dilutions of 10 μg / ml to 0.35 pg / ml antibody in the presence of 100 ng / ml human CSF-1. Controls including "no antibody, no CSF-1" and "no antibody, with CSF-1" were included to provide minimum and maximum MCP-1 release values. After 24 hours of incubation, cells were pelleted by centrifugation and supernatants were collected. The concentration of MCP-1 was measured using human CCL2 / MCP-1 DuoSet ELISA (R&D Systems DY279) following the manufacturer's instructions.
[0381] Hereinafter, this assay is referred to as the "MCP-1 inhibition assay".
[0382] The MCP-1 inhibition assay was used to compare the activity of humanized 969.g5 with chimeric Ab969.g0. Five independent assays were performed using four different donors of monocytes. In all assays, the Ab969.g5 humanized grafts exhibited surprisingly significantly lower activity than the parental chimeric antibody 969.g0. A single representative experiment is shown in Fig.13Compared with 333.0 ng / ml for 969.g5, the average IC of 969.g0 in the monocyte assay was 50 This indicates a 13.5-fold decrease in antibody potency when comparing the two antibodies using this assay format.
[0383] Ab969 was used to perform a series of experiments to show why the humanized antibody exhibits reduced activity in the MCP-1 inhibition assay. The data show that the loss of Ab969.g5 activity observed in the MCP-1 inhibition assay is attributed to the order in which the antibody and ligand are added to the target cells. The activity of both Ab969.g0 and Ab969.g5 was reduced when a competitive assay format was applied, but more importantly, a large difference in their blocking activity was detected. In order to analyze whether the lower "association rate" of humanized Ab969 can be responsible for the reduction in efficacy, a BIAcore analysis was performed. These data have identified that although the K of Ab969.g0 and Ab969.g5 D is similar, but relative to 969.g0's 2.16x10 6 M -1 s -1 , Ab969.g5 has a lower Ka of 1.57x10 6 M -1 s -1 (See Table 5). In a competitive assay, when CSF-1 and anti-CSF-1R antibodies compete for binding to the same receptor, a slower antibody on-rate may result in reduced blocking activity if the on-rate for the ligand is also high and the ligand is present at a high concentration. Human CSF-1 is known to have a particularly high on-rate of 22.19×10 6 M -1 s -1 , and the assay was performed at a high CSF-1 concentration (250 ng / ml).
[0384] To further confirm that the reduction in blocking activity of 969.g5 was due to an intrinsic property of the antibody, an ELISA was developed to measure the binding of CSF-1 to CSF-1R. This method is hereafter referred to as the "ELISA ligand-blocking assay". This assay was performed using competitive binding, in which CSF-1 and the antibody were premixed prior to application to the plate-bound CSF-1R. An assay was also performed to evaluate the effect of CSF-1 concentration on antibody activity.
[0385] A CSF-1 concentration of 1 ng / ml was used in the ligand blocking ELISA to measure the IC of 969.g0 and 969.g5. 50 When the two antibodies were tested, they appeared to have IC values of 12.83 ng / ml and 19.65 ng / ml, respectively. 50When a concentration of 10 ng / ml CSF-1 was used in the assay, the IC values of both Ab969.g0 and Ab969.g5 were 50 The difference between the two increased, but more importantly, further increased to 79.29 ng / ml vs. 268.10 ng / ml, respectively. This trend continued in the assay using 100 ng / ml CSF-1, where Ab969.g0 and Ab969.g5 gave IC values of 828.70 ng / ml and 3947.00 ng / ml, respectively. 50 Competitive assays demonstrated that Ab969.g5 was less active than Ab969.g0 in blocking the binding of CSF-1 to CSF-1R. This reduction in potency became more pronounced with increasing CSF-1 concentrations.
[0386] iv) Identification of humanized grafts of Ab 969 with comparable activity to chimeric Ab 969 in the MCP-1 inhibition assay
[0387] The Ab969 humanized intermediate graft group was prepared by transient expression to allow comparison of in vitro activity (Table 8). The corresponding chimeric antibody (Ab969.g0) and fully humanized graft (Ab969.g5) were also included in transient expression to allow direct comparison of antibody characteristics in the same batch.
[0388] Table 8:
[0389]
[0390] The in vitro activity of each antibody was tested in the MCP-1 inhibition assay. The assay format using the CSF-1 titration of a single concentration of antibody was selected because the format enables rapid screening of large antibody groups and highlights any differentiated CSF-1R blocking activity. In this assay, the relative ability of MCP-1 to release from the dose-dependent release of primary human monocytes and each antibody to block CSF-1R activity was measured by the concentration of CSF-1 when releasing MCP-1. In the presence of a titration (2 times of serial dilutions, including 18 concentrations, with a maximum concentration of 500ng / ml) of recombinant human CSF-1, monocytes were seeded in culture medium at 20,000 cells / well. The antibody of a single dose of 1 μg / ml was added. Cells were incubated for 24h and supernatants were collected. Secreted MCP-1 was measured by ELISA. The MCP-1 inhibition assay showed that antibodies Ab969.g2 and Ab969.g7 retained high CSF-1R blocking activity, with both entities being able to completely inhibit MCP-1 secretion when CSF-1 was added to monocytes at concentrations greater than 100 ng / ml ( Fig.14). In this assay, a significant loss of activity was detected for Ab969.g5, which could only inhibit MCP-1 secretion up to a CSF-1 concentration of 10 ng / ml. Similarly, antibody Ab969.g9 exhibited reduced CSF-1R blocking activity compared to Ab969.g2 and Ab969.g7.
[0391] Measurement of IC of selected Ab969 humanized grafts in the MCP-1 assay 50 To more thoroughly assess their relative ability to inhibit CSF-1 mediated monocyte activation. It was considered important to assess antibody activity using several different donors without pooling monocytes from mixed sources. Table 9 shows the IC values of antibodies accumulated from assays performed on Ab969 using 6 different donors. 50 value.
[0392] Both Ab969.g2 and Ab969.g7 humanized grafts showed comparable relative IC values to the chimeric Ab969.g0 antibody. 50 In clear contrast, Ab969.g5 exhibited much less potency in the assay (mean chimera / graft IC 50 The ratio is 19.6).
[0393] Table 9:
[0394]
[0395] v) Affinity of the humanized Ab696 antibody panel
[0396] The affinity of each Ab969 humanized antibody graft and the parent chimeric antibody was measured by BIAcore (Table 10), where three independent experiments were performed and the average was calculated. The data show the affinity (K) during the humanization process from the chimeric molecule (Ab969.g0) to the "fully humanized" antibody Ab969.g5. D ) did not appear to change. However, the antibody "on-rate" decreased as humanization proceeded beyond the Ab969.g2 graft; both Ab969.g4 and Ab969.g5 had lower K than the previous grafts. a In addition, the K a This is lower than that of Ab969.g4, potentially indicating that the mutation of the DG isomerization site to SG further reduces the antibody association rate.
[0397] Table 10:
[0398]
[0399] in conclusion:
[0400] Testing of the Ab969 humanized graft panel in several assays showed that a tyrosine residue at position 71 in the light chain (e.g., Y71) improved the activity of the antibody. Substitution of, for example, phenylalanine by Y71 resulted in a decrease in the antibody association rate relative to the parent chimeric molecule (reduced K a This resulted in a reduction in the ability of the antibody to block the binding of CSF-1 to CSF-1R, as shown in an assay monitoring the activity of CSF-1R in primary human monocytes (MCP-1 inhibition assay).
[0401] Example 4 - Molecular stability of humanized Ab696 group
[0402] i) Thermal stability
[0403] Thermal stability (measured as melting temperature, Tm) was determined by two independent methods; one method monitoring unfolding by binding of a fluorescent dye to exposed hydrophobic surfaces (Thermofluor method) and the other by calorimetric analysis (DSC), which is an orthogonal technique.
[0404] T of various grafts measured by Thermofluor against antibody 969 (in PBS pH 7.4) m A summary is given in Table 11.
[0405] Table 11
[0406]
[0407] In general, the Fab'T m Most 969 grafts were shown to be more thermostable compared to the IgG4 control.
[0408] ii) Effect of sample concentration on aggregation tendency
[0409] As a prediction of sample stability during storage, the effect of antibody concentration on stability in PBS pH 7.4 was investigated.
[0410] Experiment 1:
[0411] The antibodies were concentrated to >10 mg / ml and incubated at room temperature for 5 days. Immediately after concentration (T0), 969.g7 showed turbidity and 969.g8 showed slightly milky white. Relatively, the 969.g5 sample was judged to be clear based on visual inspection. After incubation at room temperature for 5 days, the 965.g5 sample remained clear, while the aggregation of 969.g7 and 969.g8 had further developed, each showing a large amount of precipitation.
[0412] From this study the samples can be ranked in order of resistance to aggregation under these conditions as follows: 969.g5 > 969.g8 > 969g7.
[0413] Experiment 2:
[0414] Before concentration, all three antibody samples were observed to be clear according to visual inspection, except for 969.g6 (4.68 mg / ml) showing milky white. After being concentrated to 16 mg / ml, precipitation of 969.g6 was observed after storage for 24 hours at room temperature and 4°C. However, both 969.g1 and 969.g4 remained visually clear. After 5 days of further incubation, sample 969.g1 was observed to have obvious large particles at room temperature and 4°C. As judged according to visual inspection, aggregation of sample 969.g4 was not observed at room temperature or 4°C.
[0415] This study showed that 969.g6 had some aggregation instability when stored in PBS pH 7.4 at low concentrations (4.68 mg / ml). In addition, this precipitation was exacerbated by further antibody concentration. Concentrated 969.g1 showed a slower aggregation rate, while concentrated 969.g4 remained stable for up to 5 days at either storage temperature. The order of stability for aggregation was therefore: 969.g4>969.g1>969.g6.
[0416] Experiment 3: Antibodies 969.g2, 969.g5, 969.g7, and 969.g9
[0417] Samples were analyzed immediately after concentration (T0), after overnight incubation, and 5 days after concentration. All samples were observed to be clear and without evidence of particle formation upon visual inspection prior to concentration. Immediately after concentration to 23.07 mg / ml, the 969.g7 sample showed precipitation as previously observed in Experiment 1. A slight opalescence was observed for 969.g9, which became more pronounced after storage at room temperature or 4°C for 24 hours. All other 969 grafts were observed to appear clear upon visual inspection immediately after concentration.
[0418] After 21 days of incubation, no further visible changes were observed compared to that observed after overnight incubation at room temperature; both 969.g7 and 969.g9 grafts aggregated due to concentration of the samples, however, the other samples showed no obvious visible aggregation.
[0419] In summary, the 969.g2 sample showed the least tendency to aggregate with increasing concentration. This is also consistent with the highest T as measured by Thermofluor. m Associated.
[0420] Conclusion: During expression and purification of the humanized Ab969 group, it was clear that increasing the antibody concentration to more than 10 mg / ml resulted in rapid precipitation of some humanized antibody grafts. Specifically, Ab969.g1, Ab969.g6, and Ab969.g7 formed precipitation, while Ab969.g2, Ab969.g4, and Ab969.g5 did not. This data shows that replacing glutamine with a lysine residue (K38) at position 38 in the light chain improves antibody stability when concentrated to more than 10 mg / ml.
[0421] Example 5 - In vitro analysis of Ab969.g2
[0422] i) Sequence of Ab969.g2
[0423] Ab969.g2 contains the gL7 light chain graft and the gH2 heavy chain graft. The alignment between the rat antibody (donor) V region sequence and the human germline (acceptor) V region sequence and the final humanized sequences for the light chain graft gL7 and the heavy chain graft gH2 are shown in Figure 2A and 2B middle.
[0424] The heavy chain framework residues in graft gH2 are all from human germline genes. The glutamine residue at position 1 of the human heavy chain framework is replaced with glutamic acid (E1) to improve expression and purification of homogeneous products, for example, by converting glutamine to pyroglutamic acid at the N-terminus of antibodies and antibody fragments.
[0425] The light chain framework residues in the graft gL7 are all from the human germline gene, except for residue 71 (Kabat numbering), in which the donor residue tyrosine is retained. The retention of the residues provides improved potency of the humanized antibody, as shown in Example 3.
[0426] ii) Inhibition of IL-34-dependent human monocyte activation
[0427] The activity of Ab969.g2 compared to 969.g0 was evaluated in an IL-34-dependent human monocyte assay. Two separate monocyte donors were used to perform the experiment and the average IC for inhibition of IL-34-mediated monocyte stimulation was calculated. 50 (Table 12) IC between Ab969.g2 and Ab969.g0 50 There was no significant difference.
[0428] Primary human monocytes were seeded at 20,000 cells / well in the presence of 100 ng / ml recombinant human IL-34 and dose titration of anti-CSF-1R antibody (half-log serial dilutions, including 16 concentrations, with a maximum concentration of μg / ml). The cells were incubated for 24 hours and the supernatant was collected. Secreted MCP-1 was measured by ELISA (R&D systems DY279). The graph shows the percentage inhibition of MCP-1 production compared to CSF-1 only control.
[0429] Table 12
[0430]
[0431] iii) Binding of Ab969.g2 to the SNP of human CSF-1R
[0432] Four non-synonymous single nucleotide polymorphisms (SNPs) located in the ligand binding domain of the human CSF-1R gene have been reported in the human population. These SNPs are V32G, A245S, H247P, and V279M ( Figure 1F ). Each SNP variant of human CSF-1R was generated and stably expressed in a cell line. Binding of Ab969.g2 to each SNP was confirmed by flow cytometry.
[0433] Example 6 - Analysis of Pharmacodynamic Markers in Cynomolgus Monkeys
[0434] A pharmacokinetic / pharmacodynamic (PK / PD) study using the humanized monoclonal anti-CSF-1R antibody 969.g2 was performed to confirm the pharmacological activity of the antibody in non-human primates (cynomolgus monkeys). Groups of three cynomolgus monkeys were administered a single dose of 7 mg / kg (Group 1) or 1.5 mg / kg (Group 2) of the 969.g2 antibody intravenously. The antibody was well tolerated with no adverse clinical signs. Serum samples were collected at multiple time points during the 25-day study period.
[0435] Serum concentrations of 969.g2 were measured by ELISA and pharmacokinetic analysis was performed (Table 13). PK parameters were calculated using WinNonlin software.
[0436] t 1 / 2 is the half-life of the antibody in serum.
[0437] C max is the peak concentration of the antibody in serum.
[0438] AUC is the area under the curve (integral of the concentration-time curve) and provides an indication of the total exposure to the drug.
[0439] The clearance rate is the volume of plasma that clears the drug per unit time.
[0440] Vol. Dist. is the volume of distribution, which is the apparent volume of drug distribution.
[0441] There is a good correlation between the observed and predicted values (with the exception of animal 2 which is considered an outlier). max Proportional to dose; AUC was greater than dose proportional, indicating lower clearance at higher doses. Most of 969.g2 was detected in serum.
[0442] Table 13
[0443]
[0444] The major pathway for clearance of CSF-1 is through binding to its cognate receptor, CSF-1R. Blockade of CSF-1 binding to CSF-1R is expected to increase serum concentrations of CSF-1 by preventing receptor-mediated clearance; a phenomenon that has been observed in murine models. Therefore, an increase in serum CSF-1 concentrations is a pharmacodynamic marker of CSF-1R binding and inhibition.
[0445] Both doses of 969.g2 resulted in a rapid and significant accumulation of serum CSF-1. The effect was dose-dependent, with the 7 mg / kg dose providing approximately 10-fold higher peak CSF-1 concentrations than the 1.5 mg / kg dose. The pharmacokinetic / pharmacodynamic relationship observed by normalization of CSF-1 levels followed the antibody clearance rate. For both treatment groups, CSF-1 levels returned to baseline at the end of the study. The results are shown in Fig.15a and 15b.
[0446] Fig.15a The concentration of CSF-1 in serum samples collected from cynomolgus monkeys treated with a single intravenous dose of 7 mg / kg Ab969.g2 is shown. The serum concentration of CSF-1 was measured in two independent assays. The figure shows the mean concentration of CSF-1 with standard error (squares) for three animals in Group 1 (7 mg / kg). The mean serum concentration of Ab969.g2 (circles) is also shown.
[0447] Fig.15b The concentration of CSF-1 in serum samples collected from cynomolgus monkeys treated with a single intravenous dose of 1.5 mg / kg Ab969.g2 is shown. The serum concentration of CSF-1 was measured in two independent assays. The figure shows the average concentration of CSF-1 for three animals in Group 2 (1.5 mg / kg) and the standard error (squares). The average serum concentration of Ab969.g2 (circles) is also shown.
[0448] There are two major populations of circulating human and cynomolgus monkey monocytes; (i) CD14+CD16- "typical" monocytes and (ii) CD14+CD16+ "atypical" or "resident" monocytes. Murine models have demonstrated that resident tissue macrophages (including TAMs) are derived from atypical monocyte populations. In addition, atypical monocytes are derived from further differentiation of typical monocyte populations. Circulating monocyte populations in cynomolgus monkeys dosed with 969.g2 were monitored by four-color flow cytometry of whole blood. Flow cytometry was performed using anti-cynomolgus monkey-CD45-PerCP, anti-human-HLA-DR-APC, anti-human-CD14-FITC (My4 clone), and anti-human-CD16-PE (3G8 clone) antibodies. Appropriate isotype controls were used to set gates for each antibody. Typical monocytes are defined as CD45 + HLA-DR + CD14 + CD16 - Atypical monocytes are defined as CD45 + HLA-DR + CD14 + CD16 + .
[0449] Both doses of 969.g2 promoted atypical CD14 + CD16 + Monocytes were gradually depleted during the first week of the study. Almost complete depletion of atypical monocytes was caused by the 7 mg / kg dose. The reduction in atypical monocytes by the 7 mg / kg and 1.5 mg / kg doses appeared to peak at the 4 day time point, with numbers returning to normal by day 11. Results are shown in Fig.15c Middle. Bar graph showing circulating atypical CD14 + CD16 + Mean number of monocytes and standard error at time points throughout the study (Day 0, Day 1, Day 4, Day 18 and Day 25 (D)). Mean concentration of serum CSF-1 and standard error are also plotted.
[0450] This example demonstrates that (i) antibody 969.g2 is able to bind to CSF-1R and block CSF-1 binding in cynomolgus monkeys, (ii) the pharmacological activity of antibody 969.g2 in a non-human primate model is demonstrated, (iii) antibody 969.g2 is demonstrated to selectively deplete an atypical population of cynomolgus monkey monocytes in vivo - believed to be precursors of tumor-associated macrophages, and (iv) serum CSF-1 concentration is suitable as a biomarker for measuring 969.g2 activity.
[0451] Example 7 - Inhibition of Growth of MCF-7 Breast Cancer Xenografts
[0452] Antibody 969.g2 is unable to bind to mouse CSF-1R. Therefore, in vivo mouse studies were performed using the anti-murine CSF-1R antibody Ab535 to show the utility of Ab969.g2 in treating cancer and fibrosis. Ab535 has been shown in a number of in vitro experiments to have comparable properties and activities to Ab969.g2.
[0453] Ab535 has been shown in Example 2, iii) to inhibit CSF-1 mediated monocyte survival, in Example 2, iv) with comparable affinity and in Example 2, vii) not to trigger CSF-1R internalization.
[0454] For in vivo studies of Ab535, an in vivo MCF-7 breast cancer xenograft model can be performed as follows:
[0455] This study measures the therapeutic efficacy of subcutaneously administered (sc) antibody Ab535 in immunodeficient nude mice with subcutaneous transplants of human breast cancer xenograft MCF-7 relative to control antibodies, positive controls and vehicle controls. Tumor growth inhibition is used as a treatment parameter. Human breast cancer MCF-7 is used as a subcutaneous xenograft model in immunodeficient female NMRI: nu / nu mice. The MCF-7 cell line was obtained from the tumor bank of the National Cancer Institute (USA). For experimental purposes, cells were cultured in RPMI1640 medium + 10% FCS in vitro. Cells were collected from subconfluent cultures and inoculated subcutaneously into mice. Treatment was started when the tumor size (4 to 10 mm) was palpable. Test compounds and vehicle controls were given (sc) three times a week. Positive controls were administered intravenously once a day on the 24th, 33rd and 40th days. The injection volume was adjusted individually for body weight at the time of injection. Tumor diameter was measured with a caliper three times a week. Tumor volume was calculated according to V=(length×(width)2) / 2. For calculation of relative tumor volume (RTV), the volume of each measurement day was related to the first treatment day. On each measurement day, the median and mean tumor volume for each group and the median percentage of the treatment group to the control group (T / C) value were calculated.
[0456] The results are shown in Fig.16 Ab535 showed a dose-dependent anti-tumor effect. Both doses of the control mouse IgG antibody did not cause tumor growth inhibition. The relative tumor volume was comparable to the vehicle control and the positive control that caused tumor growth inhibition.
[0457] Conclusion: The test antibody Ab535 elicited a statistically significant anti-tumor effect at the highest dose (30 mg / kg / day) in the human breast cancer xenograft MCF-7.
[0458] Example 8 - Inhibition of Growth of PC-3 Prostate Cancer in Situ
[0459] The anti-tumor and anti-metastatic efficacy of antibody Ab535 was also tested in vivo using the orthotopic prostate cancer model PC-3. The PC-3 cell line was genetically altered to constitutively express luciferase, allowing in vivo bioluminescence imaging analysis, which allows in vivo monitoring of tumor growth and ex vivo metastasis analysis in selected organs.
[0460] This research is composed of 6 experimental groups of 11 (group 5) or 12 (other all groups) male NMRI nude mice respectively after random grouping.At the 0th day, PC-3 cells were implanted in situ in the prostate of all male NMRI nude mice participating.At the 3rd day, the beginning of tumor growth was verified via in vivo bioluminescent imaging.At the 8th day, the second in vivo bioluminescent imaging was carried out and the animals suffering from tumor were randomly divided into six groups according to the imaging result, so that the average bioluminescent intensity and thus the tumor size were similar in each group.At the latter day (the 9th day), treatment was started.The animals of group 2 and group 3 received the control antibody of 30 and 10mg / kg respectively, and were subcutaneously administered 3 times per week until the 42nd day.The animals of treatment group 4 and group 5 received the antibody Ab535 of 30 and 10mg / kg respectively, and were subcutaneously administered 3 times per week until the 42nd day.The animal representative of group 1 was vehicle control and received vehicle (PBS), and was subcutaneously administered 3 times per week until the 42nd day. Animals in Group 6 represented positive controls and received 360 mg / kg control, administered intravenously once a week for four weeks (on days 10, 17, 24, and 31). During the study, bioluminescent imaging was used to monitor the growth of orthotopically implanted PC-3 tumors in vivo on days 3, 8 (randomization), 15, 22, 29, 36, and 43.
[0461] Carry out autopsy at the end of the study.Measure initial tumor weight and volume.Collect selected organs (liver, spleen and lung), take a part of each and be fixed in formalin and utilize in vitro luciferase to measure the metastasis pattern of the rest part via bioluminescence imaging analysis.In addition, collect the same part of the femur and lumbar vertebra from a leg, for utilizing in vitro luciferase to measure the metastasis pattern in bone analysis.
[0462] The in vivo bioluminescent signal consisted of both primary tumors and metastases (whole body imaging). Based on these data, tumor growth curves were calculated for all groups ( Fig.17). Tumor development was uniform in all study groups until randomization and treatment initiation. Next, vehicle control group 1 and two control antibodies RTE11 groups 2 and 3 showed regular tumor growth. For the positive control (group 6), a highly significant slowing down of tumor growth measured in vivo on day 43 was observed. When monitored by in vivo bioluminescent imaging, antibody Ab535 (groups 4 and 5) administered at 30 or 10 mg / kg, respectively, resulted in a significant slowing down of tumor growth.
[0463] Initial tumor volume and wet weight were determined during necropsy on day 44. The positive control (Group 6) resulted in a highly significant reduction in initial tumor volume and weight. Antibody Ab535 was administered at 30 mg / kg (Group 4) and a significant reduction in initial tumor volume and weight was observed. When Ab535 was administered at 10 mg / kg (Group 5), the reduction in tumor volume was significant but less than that shown in Group 4. No significant anti-tumor efficacy was observed for the control antibody.
[0464] Utilize bioluminescent imaging technology, measure initial tumor luciferase activity after autopsy.The result that obtains is comparable with the result of autopsy discovery and in vivo growth curve.Positive control (group 6) causes the height significant reduction of initial tumor luciferase activity.Antibody Ab535 (group 4) used with 30mg / kg causes the significant reduction of initial tumor luciferase activity, and when Ab535 is used with 10mg / kg (group 5), the reduction amount is lower.With respect to control antibody, no significant reduction of luciferase activity is observed.
[0465] Several other organs (liver, spleen, lung, femur and part of lumbar vertebra) were analyzed using ex vivo bioluminescent imaging. For the positive control, the femur and lumbar vertebra showed a significant reduction in luciferase activity, while for the liver and spleen, the signal reduction was just below significance. For the antibody Ab535 (Group 4) administered at 30 mg / kg, the reduction in luciferase activity of the liver was significant and for all other organs was significant. The control antibodies (Groups 2 and 3) did not result in any reduction in luciferase activity in all organs tested.
[0466] In conclusion, it was possible to demonstrate a significant anti-tumor efficacy of the antibody Ab535 in this tumor model as well as a significant anti-metastatic efficacy.
[0467] Example 9 - Effect of anti-CSF-1R antibody in the bleomycin-induced in vivo pulmonary fibrosis model
[0468] Bleomycin is an antibiotic first isolated from Streptomyces verticillatus and has been used as a chemotherapeutic agent for various cancers. The bleomycin model of pulmonary fibrosis is a well-established model and is used essentially as described in Madtes, DK et al., 1999, Am J Respir Cell Mol Biol, 20, 924-34. Detailed protocols can be found in the following documents Morschl, E., Molina, JG, Volmer, J., Mohsenin, A., Pero, RS, Hong, JS, Kheradmand, F., Lee, JJ and Blackburn, MR (2008), A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis. Am. J. Respir. Cell Mol. Biol. 39: 697-705.
[0469] All mice used are wild-type C57Blk6 female mice (20g) purchased from Harlan Labs. Use intratracheal (IT) incision instillation, wherein use Avertin to anesthetize mice, and perform tracheostomy to instill 3.5 unit doses of bleomycin or independent 50 μ l saline in 50 μ l saline as control. Processing in this way causes the inflammatory stage reaching peak value on the 7th day after bleomycin exposure and reaches maximum fibrosis phase on the 21st day after exposure. The effect of antibody Ab535 has been studied, wherein antibody is only administered in the fibrosis phase of model and is subcutaneously administered with 30mg / kg three times a week from the 9th-21st day. Animals were put to death on the 21st day, and the reading includes the measurement of soluble collagen in pathological histological analysis, BAL (bronchoalveolar lavage) fluid cell formation and BAL fluid of lung. Histopathological analysis was performed to determine the severity of pulmonary fibrosis using a modified Ehrlich scoring system to score lung injury (Hubner RH et al., 2008, Biotechniques 44:507-17). Excised lungs were inflated to 25 cm pressure with 10% formalin and processed through a series of alcohols and xylenes, embedded in paraffin, and tissue sections were deparaffinized and stained with Masson's trichrome stain prior to processing.
[0470] The amount of soluble collagen in BAL fluid was assessed using the commercially available Sircol assay kit according to the manufacturer's instructions.
[0471] The effect on the macrophage population in BAL fluid was determined using cytospin preparations. Aliquots of BAL cells were spun onto microscope slides, stained with Diff-Quick and macrophages were counted.
[0472] The results showed that therapeutic treatment with anti-CSF-1R antibody Ab535, starting at day 9, resulted in a significant reduction in bleomycin-induced lung fibrosis. Both the severity and extent of fibrosis were significantly reduced. Treated mice had reduced collagen production, improved fibrotic pathology, and improved lung barrier protection.
[0473] Fig.18a Shown are the effects of Ab535 treatment on BALF collagen concentrations compared to isotype control in bleomycin-induced lung fibrosis.
[0474] Fig.18b Ab535 treatment of bleomycin-induced lung fibrosis was shown to reduce Ehrlich scores of samples compared to treatment with isotype control, thus showing that mice treated with Ab535 had improved fibrotic pathology.
[0475] Fig.18c It was shown that Ab535 treatment of bleomycin-induced lung fibrosis reduced serum albumin concentrations compared to treatment with isotype control, thus showing that vascular permeability was improved in mice treated with Ab535.
[0476] Fig.19 Representative images of histopathological analysis of lungs from saline control, bleomycin + isotype control, and bleomycin + Ab535 treated animals are shown. Animals treated with Ab535 had greatly reduced lung fibrosis compared to isotype control, bleomycin treated animals.
[0477] Example 10 - Effect of anti-CSF-1R antibodies in an adenosine deaminase-deficient model of pulmonary fibrosis
[0478] Adenosine is a potent signaling nucleoside, whose level increases when cells are subjected to stress or damage, and produces a wide variety of responses when adenosine engages its specific G protein-coupled receptors. Adenosine deaminase (ADA) is a purine metabolic enzyme that converts adenosine into inosine. Mice knocking out ADA have been produced and shown to have elevated adenosine levels in serum and tissues such as kidney, liver and lung (Blackburn, MR et al., 1998, J Biol Chem, 273 (9): 5093-5100). These mice present features of chronic lung disease, such as alveolar destruction, airway inflammation and excessive mucus production, which is associated with elevated levels of adenosine in the lungs (Blackburn MR et al., 2000, J Exp Med, 192: 159-70). These effects cause mice to die at three weeks of age due to respiratory distress. Exogenous ADA administration using a low-dose regimen reduces adenosine levels and prolongs the lifespan of these mice, allowing a model of pulmonary fibrosis to be developed (Chunn JL et al., 2005, J Immunol 175: 1937-46, Pedrosa M et al., 2011, PLoS One, 6 (7): e22667). In this model, a slow increase in adenosine levels is associated with an increase in profibrotic mediators in the lungs, including TGFβ-1, increased collagen deposition in lung tissue, and increased pulmonary fibrosis pathology. In order to study the role of molecules with anti-fibrotic potential, ADA-deficient mice were maintained on a low-dose exogenous ADA regimen for several weeks, then ADA treatment was stopped and potential anti-fibrotic agents were administered.
[0479] The effect of anti-CSF-1R antibody Ab535 was studied in an ADA knockout mouse model of pulmonary fibrosis. In this model, enzyme-deficient mice were maintained with ADA enzyme therapy from 1 to 21 days after birth. ADA-polyethylene glycol (PEG) conjugates (Young HW et al., 2004, J Immunol 173: 1380-89) were prepared and intramuscular injections (0.625, 1.25, 2.5, 2.5 and 2.5 units, respectively) were administered on days 1, 5, 9, 13 and 17 after birth, followed by an intraperitoneal injection of 5 units on day 21. No further enzyme was administered after day 21. Ab535 was administered subcutaneously three times a week from day 25 (after birth) at a volume of 100 μl, 30 mg / kg until the animals were killed on day 42.
[0480] Animals were sacrificed on day 42, and readouts included histopathological analysis of the lungs, BAL fluid cellularity, and quantification of soluble collagen in the BAL fluid. Histopathological analysis was performed to determine the severity of pulmonary fibrosis using a modified Ehrlich scoring system to score lung injury (Hubner et al., 2008, Biotechniques 44:507-17). Excised lungs were inflated to 25 cm pressure with 10% formalin and processed through a series of alcohols and xylenes, embedded in paraffin, and tissue sections were deparaffinized prior to processing and stained with Masson's trichrome stain.
[0481] The amount of soluble collagen in BAL fluid was also assessed using the commercially available Sircol assay kit according to the manufacturer's instructions.
[0482] The effect on the macrophage population in BAL fluid was determined using cytospin preparations. Aliquots of BAL cells were spun onto microscope slides, stained with Diff-Quick and macrophages were counted.
[0483] The results showed that therapeutic treatment with anti-CSF-1R antibody Ab535 significantly reduced lung fibrosis in ADA-deficient mice. Treated mice had reduced collagen production, improved fibrotic pathology, and improved lung barrier function and protection.
[0484] Fig.20a It was shown that treatment of ADA-deficient mice with induced lung fibrosis with Ab535 reduced BALF collagen concentrations compared to treatment with isotype control.
[0485] Fig.20b Treatment of ADA-deficient mice with induced lung fibrosis with Ab535 was shown to reduce Ehrlich scores of samples compared to treatment with isotype control, thus showing that mice treated with Ab535 had improved fibrotic pathology.
[0486] Fig.20c It was shown that treatment of ADA-deficient mice with induced pulmonary fibrosis with Ab535 reduced the concentration of albumin in the serum compared to treatment with isotype control, thus showing that vascular permeability was improved in mice treated with Ab535.
[0487] Fig.20d It was shown that ADA-deficient mice with induced pulmonary fibrosis that received Ab535 had reduced numbers of macrophages in the BAL fluid.
[0488] Fig.21Representative images of histopathological analysis of lungs from normal mice (ADA+) and ADA-deficient mice (ADA-) with induced pulmonary fibrosis treated with isotype control or Ab535 are shown. In ADA- mice, animals treated with Ab535 had greatly reduced pulmonary fibrosis compared to isotype controls.
[0489] Thus, it has been shown that treatment with anti-CSF-1R antibodies in two mouse models of pulmonary fibrosis is effective in treating fibrotic disease.
[0490] The present invention includes the following embodiments:
[0491] 1. An anti-CSF-1R antibody comprising a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises the sequence shown in SEQ ID NO: 23, and wherein the variable domain of the light chain comprises the sequence shown in SEQ ID NO: 15.
[0492] 2. The anti-CSF-1R antibody according to embodiment 1, wherein the antibody molecule is selected from a complete antibody molecule having full-length heavy and light chains or a fragment thereof, for example selected from the group comprising Fab, modified Fab', Fab', F(ab')2, Fv and scFv fragments.
[0493] 3. The anti-CSF-1R antibody according to embodiment 1 or embodiment 2, wherein the heavy chain further comprises a heavy chain constant domain, and the light chain further comprises a light chain constant domain.
[0494] 4. The anti-CSF-1R antibody according to embodiment 1 or embodiment 3, which has a heavy chain comprising the sequence shown in SEQ ID NO: 27 and a light chain comprising the sequence shown in SEQ ID NO: 19, wherein the C-terminal lysine of the antibody heavy chain is present or absent.
[0495] 5. The anti-CSF-1R antibody according to any one of embodiments 1 to 4, which has an effector molecule or a reporter molecule linked thereto.
[0496] 6. The anti-CSF-1R antibody according to any one of embodiments 1 to 5, which has a binding affinity for human CSF-1R of 10 pM or less.
[0497] 7. A first isolated DNA sequence and a second isolated DNA sequence, wherein the first isolated DNA sequence encodes the heavy chain of the antibody according to any one of embodiments 1 to 6, and the second isolated DNA sequence encodes the light chain of the antibody according to any one of embodiments 1 to 6.
[0498] 8. A cloning or expression vector comprising the first isolated DNA sequence and the second isolated DNA sequence according to embodiment 7, wherein the first isolated DNA sequence encodes the heavy chain and the second isolated DNA sequence encodes the light chain.
[0499] 9. A first cloning or expression vector and a second cloning or expression vector, wherein the first cloning or expression vector comprises a first isolated DNA sequence encoding the heavy chain according to embodiment 7, and the second cloning or expression vector comprises a second isolated DNA sequence encoding the light chain according to embodiment 7.
[0500] 10. The vector according to embodiment 8 or embodiment 9, wherein the vector comprises the sequence shown in SEQ ID NO: 28 and SEQ ID NO: 20 or the sequence shown in SEQ ID NO: 24 and SEQ ID NO: 16.
[0501] 11. A host cell comprising the cloning or expression vector according to embodiment 8 or 9.
[0502] 12. A method for preparing the antibody according to any one of embodiments 1 to 6, the method comprising culturing the host cell of embodiment 11 and isolating the antibody.
[0503] 13. A pharmaceutical composition comprising the antibody according to any one of embodiments 1 to 6 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
[0504] 14. The pharmaceutical composition according to embodiment 13, further comprising other active ingredients.
[0505] 15. The antibody according to any one of embodiments 1 to 6 for use as a medicament.
[0506] 16. The antibody according to any one of embodiments 1 to 6 for use in treating cancer.
[0507] 17. The antibody according to any one of embodiments 1 to 6, for use in treating a fibrotic disease.
[0508] 18. The pharmaceutical composition according to embodiment 13 or 14 for use as a medicament.
[0509] 19. The pharmaceutical composition according to embodiment 13 or 14, for use in the treatment of cancer.
[0510] 20. The pharmaceutical composition according to embodiment 13 or 14, for use in the treatment of fibrotic diseases.
[0511] 21. Use of the pharmaceutical composition according to embodiment 13 or 14 in the preparation of a medicament for treating or preventing cancer.
[0512] 22. Use of the pharmaceutical composition according to embodiment 13 or 14 in the preparation of a medicament for treating or preventing a fibrotic disease.
[0513] 23. The antibody for use according to embodiment 16, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic carcinoma, endometrial cancer, cervical cancer, bladder cancer, kidney cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer, and ovarian cancer.
[0514] 24. The antibody for use according to embodiment 17, wherein the fibrotic disease is selected from: pulmonary fibrosis such as idiopathic pulmonary fibrosis and cystic fibrosis, renal fibrosis, cirrhosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloid, myocardial infarction, scleroderma and arthrofibrosis.
[0515] 25. The anti-CSF-1R antibody for use according to embodiment 17, wherein the fibrotic disease is selected from idiopathic pulmonary fibrosis and cystic fibrosis.
[0516] 26. The use according to embodiment 19 or 21, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic carcinoma, endometrial cancer, cervical cancer, bladder cancer, kidney cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer.
Claims
1. An anti-CSF-1R antibody or a binding fragment thereof, comprising a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises the sequence shown in SEQ ID NO: 23, and wherein the variable domain of the light chain comprises the sequence shown in SEQ ID NO:
15.
2. The anti-CSF-1R antibody or binding fragment thereof according to claim 1, wherein the antibody is a complete antibody molecule having full-length heavy and light chains or a binding fragment thereof, wherein the binding fragment is a Fab, modified Fab', Fab', F(ab')2, Fv or scFv fragment. 3 . The anti-CSF-1R antibody or binding fragment thereof according to claim 1 , wherein the antibody is a binding fragment comprising a heavy chain constant domain and a light chain constant domain. The anti-CSF-1R antibody or binding fragment thereof according to claim 1, which has an effector molecule or a reporter molecule linked thereto. 5 . The anti-CSF-1R antibody or binding fragment thereof according to claim 1 , which has a binding affinity for human CSF-1R of 10 pM or less.
6. A first isolated DNA sequence and a second isolated DNA sequence, wherein the first isolated DNA sequence encodes the heavy chain of the antibody or its binding fragment according to any one of claims 1 to 5, and the second isolated DNA sequence encodes the light chain of the antibody or its binding fragment according to any one of claims 1 to 5.
7. A cloning or expression vector comprising a first isolated DNA sequence encoding a heavy chain and a second isolated DNA sequence encoding a light chain according to claim 6.
8. A first cloning or expression vector and a second cloning or expression vector, wherein the first cloning or expression vector comprises a first isolated DNA sequence encoding a heavy chain according to claim 6, and the second cloning or expression vector comprises a second isolated DNA sequence encoding a light chain according to claim 6.
9. The vector according to claim 7 or claim 8, wherein the vector comprises the sequences shown in SEQ ID NO: 24 and SEQ ID NO:
16.
10. A host cell comprising the cloning or expression vector according to claim 7 or 8.
11. A method for preparing the antibody or binding fragment thereof according to any one of claims 1 to 5, the method comprising culturing the host cell according to claim 10 and isolating the antibody or binding fragment thereof.
12. A pharmaceutical composition comprising the antibody or binding fragment thereof according to any one of claims 1 to 5 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
13. The pharmaceutical composition according to claim 12, further comprising other active ingredients.
14. Use of the pharmaceutical composition according to claim 12 or 13 in the preparation of a medicament for treating or preventing cancer, wherein the cancer is selected from breast cancer and prostate cancer.
15. Use of the pharmaceutical composition according to claim 12 or 13 in the preparation of a medicament for treating or preventing a fibrotic disease, wherein the fibrotic disease is pulmonary fibrosis.
Citation Information
Patent Citations
Antibody-metal ion complexes
US4741900A
Recombinant antibodies and methods for their production in which surface residues are altered to cysteine residues for attachment of effector or receptor molecules
US5219996A
Humanized immunoglobulins
US5585089A
Device for centering and clamping a component with a view to lapping it using an expansion lap
US5667425A
Conjugates of hydroxyalkyl starch and a protein
US8017739B2
